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Abstract
Tuberculosis and parasitic diseases, such as giardiasis, amebiasis, leishmaniasis and trypanosomiasis, all 
urgently require improved treatment options. Recently, it has been shown that anti-tubercular bicyclic 
nitroimidazoles such as pretomanid and delamanid have potential as repurposed therapeutics for the 
treatment of visceral leishmaniasis. Here we show that pretomanid also possesses potent activity against 
Giardia lamblia and Entamoeba histolytica, thus expanding the therapeutic potential of nitroimidazo-
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oxazines. Synthetic analogs with the novel nitroimidazopyrazin-one/-e bicyclic nitroimidazole 
chemotype were designed, synthesized and structure activity relationships generated. Selected 
derivatives had potent antiparasitic and antitubercular activity whilst maintaining drug-like properties 
such as low cytotoxicity, good metabolic stability in liver microsomes and high apparent permeability 
across Caco-2 cells. The kinetic solubility of the new bicyclic derivatives varied, and was found to be a 
key parameter for future optimization. Taken together, these results suggest promising subclasses of 
bicyclic nitroimidazoles containing different core architectures have potential for further development.
Introduction
Infectious diseases are an enormous global health burden. The nitroimidazole class of antibiotics, 
exemplified by metronidazole (1, Figure 1), has a long history of use to treat bacterial and parasitic 
infections.1 The mode of action of nitroimidazoles involves partial reduction of the nitro group and 
subsequent decomposition of the compound to give toxic radical species that cause DNA and protein 
damage.1 The nitro group is activated by different mechanisms, with multiple enzymes involved in 
electron transfer reactions in different target organisms, which accounts for the remarkably broad spectra 
of action of the class. More recently, there have been issues with clinical efficacy that are accompanied, 
in some cases, by development of resistance, which has prompted re-examination of this old, but still 
widely used drug class.
New clinical applications of “old” nitroimidazoles and the development of novel nitroimidazoles with a 
bicyclic core scaffold architecture have significant potential to address the emergent unmet medical need 
imparted by resistant bacteria and parasites. For example, secnidazole (2, Figure 1) was recently 
approved in the USA for the treatment of bacterial vaginosis, despite being available earlier as a generic 
in many jurisdictions.2,3 A pediatric formulation of benznidazole 3 (Figure 1), a 2-nitroimidazole used 
for treatment of Chagas disease caused by the parasite Trypanosoma cruzi, gained FDA approval in 2017 
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for use in children.4 The Drugs for Neglected Diseases initiative (DNDi) is currently investigating 
fexinidazole (4, Figure 1) as a candidate for oral treatment of human African trypanosomiasis (HAT), a 
parasitic infection caused by Trypanosoma brucei spp. that is a public health threat to ~70 million people 
in Africa.5 Furthermore, bicyclic nitroimidazoles, such as delamanid (5, Figure 1) and pretomanid (6, 
PA-824), are promising new antimicrobials being developed for the treatment of tuberculosis (TB),6 the 
number one cause of death from infectious diseases and the ninth leading cause of death worldwide.7 
The nitroimidazo-oxazole 5 gained conditional approval in the European Union in 2014 for the treatment 
of drug resistant TB. This agent was derived from CGI 17341 (7)8,9  and overcame the mutagenic liability 
of 7 (Figure 1).10,11 Meanwhile, 6 was developed concurrently with 5, and is currently in Phase III trials. 
The PK profile of 6 is superior to 5 and this permits once daily dosing, although 6 is less potent.12
Figure 1. Monocyclic nitroimidazoles 1-4 and the bicyclic variants delamanid (5), pretomanid (6), CGI 17341 (7) 
and (R)-PA-824 (8).
Investigations on how 5 and 6 inhibit M. tuberculosis under aerobic and anaerobic growth conditions 
revealed an interesting dual mode of action. Transcriptional profiling of M. tuberculosis treated with 6 
under aerobic growth conditions, gave a response consistent with both the inhibition of cell wall mycolic 
acid biosynthesis and also respiratory poisoning.13 Additionally, it was shown that deazaflavin dependent 
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nitroreductase (Ddn) catalyzed reduction of 6 to the des-nitro 9 metabolite and that this process generated 
nitric oxide.14 Nitric oxide could be detected in Mycobacterium bovis cells treated with 6 under both 
aerobic and anaerobic growth conditions and the rate of NO release in M. bovis cells correlated with the 
anaerobic activities for a series of analogues, supporting the premise that this is the mode of action of 
this class under anaerobic growth conditions in M. tuberculosis.14 In comparison, 1 is only active against 
non-replicating M. tuberculosis under anaerobic growth conditions (<0.06% oxygen).15 
Nitroimidazoxazine 6 was also investigated for activity against other kinetoplastid organisms in multiple 
developmental life stages including L. donovani (promastigote and amastigote), T. brucei brucei 
(procyclic and bloodstream) and T. cruzi (epimastigote and amastigote),16 with the findings prompting 
further mode of action studies in L. donovani. Compound 8, the R- enantiomer of 6, was shown to be 
more effective than the S- enantiomer in an in vivo model of visceral leishmaniasis.16 Recently, an 
NAD(P)H oxidase was identified as the activating nitroreductase (NTR2) for the nitroimidazo-oxazole/-
oxazine.17 However, the monocyclic sulfone metabolite of 4, known to be activated by a type I 
nitroreductase, 18 was only marginally activated by NTR2.17 These results support the hypothesis that 6 
is activated by an alternative mechanism of action in L. donovani under these culture conditions and 
illustrates the biological complexity of the mode of action of various nitroimidazoles.
In the course of development of 5 and 6 as treatments for tuberculosis, over 1000 derivatives were 
prepared.19 The structure activity relationships disclosed to date mostly include compounds with 
modifications to the aryl side chain, with a smaller number of variants that alter the bicyclic core structure 
(Figure 2A). The nitro group and stereochemistry of the side chain have been shown to be critical for 
activity as both 8 and S-des-nitro-PA-824 (9) derivatives were inactive in in vitro cultures at 50 μM.16 
An analog with the nitro group at the 3ʹ position was shown to be inactive, clarifying that the 2ʹ position 
of the nitro group on the 6 bicyclic scaffold is important for activity.20 Replacement of the benzylic 
oxygen with nitrogen led to an amino linked series (10a-b) with favorable in vitro activity and solubility 
Page 4 of 90
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
properties.21,22 Modification of the imidazole ring to a pyrazole (11a) or triazole (11b) was detrimental 
to M. tuberculosis activity, as was replacement of the oxygen heteroatom in the oxazine ring with 
sulfoxide (11c), sulfone (11d), amino (11e) or methylene (11f) groups, although a sulfur (11g) 
heteroatom in the ring was tolerated.23
More recent efforts have explored the activity of bicyclic nitroimidazoles against the kinetoplastids 
Leishmania and trypanosomes. DNDi is currently investigating additional nitro-imidazooxazines for 
development against visceral leishmaniasis,24 including DNDI-8219 (12) and DNDI-0690 (13), 6- and 
7-substituted imidazooxazines, as two promising backup candidates.25,26 Interestingly, 
nitroimidazothiazine oxides 14a-d were found to display favorable activity against T. b. brucei, an animal 
infective strain that is commonly used as a model of HAT.19 Moreover, a “thio-delamanid” derivative 
(15) proved to be efficacious against T. cruzi, although it was inactive against Leishmania.27 These 
studies demonstrate that the selectivity profile toward different parasites can be altered by structural 
modifications of the bicyclic scaffold and that different subclasses of the bicyclic nitroimidazoles expand 
the potential therapeutic scope of this antimicrobial class.
We reasoned that bicyclic nitroimidazole derivatives could have potential against an even wider range of 
organisms than Leishmania and trypanosomes. Previously we found that 4(5)-nitroimidazoles (16)28 had 
potent activity against Giardia lamblia, Entamoeba histolytica, Trichomonas vaginalis and Clostridium 
difficile (Figure 2B) and therefore it was hypothesized that 6 might also have activity against these 
organisms. Anaerobic protozoa such as G. lamblia and E. histolytica and the anaerobic bacteria C. 
difficile occupy the gut under reduced oxygen tension and cause diarrheal infections. These organisms 
spread by the fecal oral route through stable cyst forms for the protozoa or through spores for C. difficile. 
Metronidazole 1 can be used therapeutically for infections caused by these organisms, but alternative 
treatment options are desirable. Furthermore, cyclizing the 4(5)-nitroimidazoles 16 from the 1′ imidazole 
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ring position to the carboxamide nitrogen could produce new bicyclic nitroimidazopyrazin-one/-e 
scaffolds. These could potentially extend the spectra of biological activity to include M. tuberculosis and 
result in altered structure activity relationships against a panel of parasitic organisms. Previous studies 
have shown that compounds containing the imidazopyrazinone scaffold have a range of different 
biological activities, including agonism of the GABAA receptor29, antagonism of the 
ionotropic transmembrane receptor,30,31 modulation of ion channels to control arrhythmia32 and 
inhibition of M. tuberculosis glutamine synthetase33. However, no studies have investigated the 
antimicrobial activity of a nitrated derivative of this class.
We now report the findings from an evaluation of 6 against a wide range of organisms, and the subsequent 
design, synthesis and biological evaluation of novel bicyclic nitroimidazoles, nitroimidazopyrazinones 
(17) and nitroimidazopyrazines (18) (Figure 2B), derived from the 4(5)-nitroimidazole scaffold 16 
previously reported.28 Given the potential for activity against many different organisms, compounds were 
screened against a wide range of microorganisms including: G. lamblia, E. histolytica, T. b. brucei, L. 
donovani, M. tuberculosis, C. difficile, Cryptoccoccus neoformans, Candida albicans and representative 
ESKAPE bacteria: Escherichia coli, Staphylococcus aureus, Klebsiella pneumoniae, Pseudomonas 
aeruginosa and Actinetobacter baumannii. Derivatives were counter-screened for cytotoxicity against 
mammalian liver and kidney cell lines. Preferred derivatives with favorable antimicrobial or antiparasitic 
activity were then evaluated for therapeutic properties including metabolic stability, plasma protein 
binding and intestinal permeability. Most of the compounds were also assessed for aqueous kinetic 
solubility. This report presents the first description of structure activity relationships and evaluation of 
nitroimidazopyrazin-ones/es for antimicrobial and antiparasitic activity with therapeutic potential.
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Figure 2. A) Structural variation of bicyclic nitroimidazoles described in the literature and B) the novel 
nitroimidazopyrazinones and nitroimidazopyrazinones, developed by cyclizing the 4(5)-nitroimidazole 
framework, described here.
Chemistry
Design and Synthesis of Bicyclic Nitroimidazoles with Variation at R1, R2 = R3 = H
In previous work28 a set of amide-substituted monocyclic nitroimidazoles were prepared and it was 
hypothesized for this study that linking the amide and imidazole nitrogen could form a bicyclic 
nitroimidazopyrazinone system, similar to the pretomanid 6 core (Figure 2B). A library of 
nitroimidazopyrazinones 17a-t were prepared with different functional groups at R1 designed to explore 
a range of physicochemical properties (Scheme 1). Initial biological results indicated that benzylic R1 
groups were favorable for antimicrobial and antiparasitic activity. The library was therefore tailored to 
contain analogs with a number of different benzyl substituted R1 groups (17b-j), including derivative 17c 
with a 4-OCF3-substituted benzyl group similar to pretomanid, and analogs with substitutions at the 3′ 
and 2′ positions. Compound 17k was prepared with R1 = CH2-(2-pyridyl) to introduce a hydrogen bond 
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acceptor and to impart more polarity and improve aqueous solubility. A methyl group was introduced at 
the benzylic position (17l) to increase the lipophilicity, bulk and potentially restrict the conformation of 
the side chain. Two phenethylene derivatives (17m-n) were prepared to investigate the effect of spacing 
the aromatic ring further from the bicyclic core. Derivatives with polar side chain R1 groups were also 
synthesized, including ethyl acetate 17o, ethyl hydroxyl 17p, morpholine derivatives 17q-r and the 
carboxamide group (17s). Compound 17t with R1 = cyclohexyl group was prepared to investigate the 
effect of a bulky aliphatic group at this position.
Initially, nitroimidazopyrazinones 17a-f, 17k-l, 17n and 17t were prepared from 4(5)-nitroimidazole 
carboxamides 16a-f , 16k-l, 16n and 16t28 by cyclizing the 1′ imidazole to the 2′ free amide nitrogen 
(route 1, Scheme 1). This was achieved by alkylating 4(5)-nitroimidazoles with bromoacetaldehyde 
diethyl acetal under basic conditions (K2CO3) which strongly favored the 4-nitro regioisomer product.34 
Secondly, microwave heating (µW 120°C) of 19a-f, 19k-l, 19n and 19t under acidic conditions afforded 
the bicyclic products 17a-f, 17k-l, 17n and 17t. This synthesis was based on the preparation of des-nitro-
imidazopyrazinone 20a, as previously described by Prévot and Leumann;35 however, microwave heating 
at higher temperatures and for shorter periods than conventional reflux facilitated analog generation for 
both steps. Secondly, inclusion of a cosolvent (aq. 2M HCl :1,4-dioxane 1:1) was necessary to solubilize 
the secondary amide starting material and achieve conversion to the desired products 17b-f, 17k-l, 17n 
and 17t. With this approach, products often precipitated from the reaction mixture and could be isolated 
in high purity by filtration and washes (H2O) alone, especially if the intermediate had been purified by 
chromatography. Alternatively, the products were purified by recrystallization. In the 1H NMR, the 
imidazopyrazinone R2 and R3 proton groups were typically two doublets (J = ~5.9 Hz) each integrating 
for 1 proton at ~ δ7.4 ppm and ~ δ7.6 ppm, respectively. Furthermore, both NMR (2D HMBC) 
experiments and an X-ray crystal structure of 17a confirmed the 2-position of the nitro group (Supporting 
Information, Figure S1).
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A second approach to prepare bicyclic nitroimidazoles 17g-j, 17m, 17o and 17q-s was developed as 
shown in route 2, Scheme 1. This method was more convergent as it eliminated the need to prepare 4(5)-
nitroimidazole intermediates of each derivative. Route 2 involved alkylation of 17a with alkyl halides 
under basic conditions (carbonate base) to form 17g-j, 17m, 17o and 17q-s. This approach also produced 
the minor O-alkylated regioisomer in some cases. This was considered advantageous because the 
alternative pyrazine ring was anticipated to have different biological activity and properties. In all cases, 
use of K2CO3 or Cs2CO3 in DMF resulted in > 10:1 ratio of the pyrazinone to pyrazine derivatives. 
Reaction with Ag2CO3 in toluene and heating as described in the literature,36,37 was briefly explored and 
found to increase the ratio of the minor imidazopyrazine isomer, with pyrazinone:pyrazine ratios of 2:1 
for 17g:18g and 17i:18i. Unfortunately, the Ag2CO3/toluene method resulted in unreacted starting 
material and a greater number of side products compared to K2CO3 or Cs2CO3 in DMF. This complicated 
the separation of 18g to the required >95% purity for biological assay. Therefore, isomers 17m and 18m 
were prepared using K2CO3 in DMF.
Nitroimidazopyrazines were readily distinguished from nitroimidazopyrazinones as they were more 
lipophilic, and thus were more strongly retained on C18 silica and more weakly retained on normal phase 
silica. Furthermore, in the 1H NMR the resonance due to the OCH2 of 18i and 18m was 0.4–0.6 ppm 
further downfield than the corresponding resonance due to the NCH2 group in the pyrazinone scaffold 
(eg 18i/17i δ 5.64 vs 5.21 ppm). In the 13C NMR spectrum, the corresponding OCH2 resonance was also 
shifted 17–19 ppm downfield for 18i and 18m compared to the corresponding NCH2 resonance (eg 
18i/17i δ 62.7 vs 45.7 ppm).
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Scheme 1. Synthesis of imidazopyrazin-ones/-es 17a-t, 18i and 18m by route 1) condensation and dehydration 
via nitroimidazole carboxamide intermediates or route 2) alkylation of 17a. i) Bromoacetaldehyde diethyl acetal, 
K2CO3, µW 180 °C, 69%–quant. yield, ii) 2M aq. HCl (10 vol), 1,4-dioxane (10 vol), µW 120 ºC, 42–87%, (17a: 
5% aq. HCl, reflux, 66%); iii) alkyl/benzyl halide, K2CO3/Cs2CO3, DMF, rt – µW 120 ºC or Ag2CO3/toluene, 80 
ºC as detailed in the experimental, 3-84% iv) K2CO3, MeOH, rt, 45%. Compounds 18g-h and 18q were detected 
but not isolated in pure form.
Des-nitro Derivatives
Des-nitro derivatives 20b-c were prepared as negative control compounds, essentially as described for 
the nitrated series above (Scheme 2). It was hypothesized that these compounds should be biologically 
inactive if the parent compounds had a mechanism of action involving reduction of the nitro group.
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Scheme 2. Synthesis of des-nitro imidazopyrazinones 20b-c. i) (COCl)2, cat. DMF, DCM, 0 °C  rt, then conc. 
NH4OH, 73%28 ii) SOCl2, reflux, then benzyl amine, 69%; iii) bromoacetaldehyde diethyl acetal, K2CO3, µW 120–
180 °C, 81–92%; iv) For 20a: 5% aq. HCl, reflux, 50%; For 20b: 5% aq. HCl, 80 °C, 39%; v) 4-fluorobenzylamine, 
K2CO3, DMF, rt, 19%.
Design and Synthesis of Nitroimidazopyrazin-ones/es with Modifications at R2, R3
We then explored different variations at the R2 and R3 positions, established a shortened route to 
synthesize the imidazopyrazinone core and further investigated the activity of the imidazopyrazine 
scaffold (Scheme 3). Both core scaffolds were prepared with three different combinations of R2 and R3 
groups in order to assess how functionalization at these sites could affect activity against different 
organisms. Since benzyl groups at R1 were favorable for biological activity, derivatives 24a-e containing 
R2 = Ph and R3 = H, but including polar substituents (CH2CH2OAc or CH2CH2OH) at R1 to counteract 
the increase in compound lipophilicity, were prepared. The effect of a methyl group at R2 = CH3, as a 
small, non-polar substituent (derivatives 25a-m) was also assessed. For the series with R2 = CH3, both 
polar and non-polar substituents at R1, including R1 = CH2CH2OAc, CH2CH2OH and several preferred 
benzyl derivatives were investigated. Lastly, matched pair analogs with R2 = R3 = CH3 (26a-i) with the 
preferred benzyl substituents at R1 were prepared.
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The synthesis of the imidazopyrazinone 24a (R2 = Ph) was initially performed as in Scheme 3 in a similar 
manner as described earlier. Intermediate 16a was alkylated with 2-bromoacetophenone at room 
temperature with K2CO3 as a base catalyst to yield 27a, which was then purified by silica 
chromatography. The condensation-dehydration cyclization of 27a was achieved with 2M aq. HCl and 
1,4-dioxane under microwave irradiation to form the phenyl substituted imidazopyrazinone core 24a. To 
synthesize the imidazopyrazinone cores with R2 = CH3 (25a) and R2 = R3 = CH3 (26a), a more concise 
synthesis was designed that involved a two-step, one-pot tandem alkylation-dehydration reaction 
(Scheme 3). For 25a and 26a, this procedure worked well. The conditions were mild as both steps of the 
reaction (alkylation and condensation-dehydration) proceeded at room temperature and the products were 
obtained in high purity after filtration and washes (H2O and MeOH) of the precipitate (67% yield over 
two steps). The one pot, two-step methodology was also tested for 24a (R2 = phenyl), although 
conversion and yields were reduced (40% isolated yield with product of 57% purity: Abs% UV254 nm 
LCMS) due to impurities that formed in both steps because of the different reactivity of the alkylation 
and condensation-dehydration steps. In addition, product 24a was slightly soluble in the methanol used 
in the wash step to remove more non-polar impurities. An intermediate work-up procedure, or 
optimization of the initial alkylation conditions could be explored to improve this method for 24a.
Alkylation of imidazopyrazinones 24a, 25a and 26a under basic conditions provided both the N- and O- 
alkylated regioisomers that were readily separated by chromatography. Alkylation conditions that used 
heating in the presence of Cs2CO3 generally favored the O-alkylated imidazopyrazine product. The 
method employed here was sufficient to provide both possible isomers for biological evaluation, but 
further optimization of the reaction conditions could be explored in the future to alter the ratio of N- to 
O- alkylated product.38 Again, the acetate groups were removed using K2CO3/MeOH to give the 
nitroimidazopyrazin-one/-es 24d-e and 25d-e.
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 Scheme 3. Synthesis of nitroimidazopyrazinon-one/-es 24a-e, 25a-m and 26a-i with variations at R2 and R3. i) 2-
Bromoacetophenone, K2CO3, DMF, rt, 60%; ii) 2M HCl, 1,4-dioxane, µW 120 ºC, 84%; iii) 25a & 26a: α-halo 
ketone, K2CO3, DMF, rt; iv) 25a & 26a: 2M HCl, 1,4-dioxane, rt, 40–67% over two steps; v) K2CO3 or Cs2CO3, 
DMF, rt – µW 80 ºC, 41–90% yield inclusive of both isomers; vi) K2CO3, MeOH, rt, 10–83% yield. Compound 
25k was detected but not isolated.
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Results and Discussion
Antiparasitic and Antimicrobial Activity of Pretomanid
Both pretomanid 6 and its enantiomer 8 were found to be ~2-fold more active than metronidazole 1 
against G. lamblia (Table 1). Both enantiomers also had activity against E. histolytica, with 8 active at 
comparable levels to 1, and 6 ~2-fold less active than 1. Compound 6 had moderate activity against C. 
difficile (MIC = 4 µg/mL), which was 8-fold less potent than metronidazole 1 (MIC = 0.5 µg/mL) (Table 
1). These results expand the spectrum of action of 6, which was previously described to inhibit M. 
tuberculosis, Leishmania spp. and Trypanosoma spp.16,26 The enantiomers 6/8 have been reported to have 
more significant differences in activities against L. donovani, trypanosomes and M. tuberculosis.16 For 
example, 8 was ~5-fold more active than 6 against L. donovani in both the promastigote and amastigote 
(intracellular macrophage) assays.16 While 6 had weak activity against T. cruzi and T. b. brucei in the 
parasite life stages relevant to mammalian infection, 8 had slightly enhanced activity, similar to the 
results against L. donovani.16 In contrast, 8 was inactive against M. tuberculosis.39 Compound 8 has 
previously been shown to bind to the M. tuberculosis Ddn enzyme involved in reductive activation of 6, 
but it could not be turned over by the enzyme.39 These differences in selectivity of the enantiomers 6 and 
8 likely indicate differences in the mode of action, respective targets, or uptake of compound by the 
respective organisms. Nonetheless, the results suggest that 6 or newer derivatives may also be repurposed 
toward enteric parasites. More potent compounds could also potentially be identified in the future by 
screening a library of pretomanid analogs from the TB alliance/DNDi collections, given that more than 
1000 analogs have been prepared.19
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Table 1. Activity of pretomanid (6) against enteric pathogens. 
Antiparasitic
IC50 (µM) (pIC50 ± SE)
Antibacterial
MIC (µg/mL) 
Compound
G. lamblia E. histolytica C. difficile
Metronidazole (1) 7.2 (5.1 ± 0.02) 4.3 (5.4 ± 0.02) 0.5
Pretomanid (6) 3.0 (5.5 ± 0.02) 9.3 (5.0 ± 0.03) 4
(R)-PA-824 (8) 3.2 (5.5 ± 0.08) 5.3 (5.3 ± 0.08) N.D
SAR of Bicyclic Nitroimidazoles with Variation at R1, R2 = R3 = H
Given the broad activity of pretomanid 6, bicyclic nitroimidazoles 17a-t, 18i and 18m were tested against 
a wide panel of organisms. These organisms included M. tuberculosis grown under aerobic (normoxic) 
and non-replicating (hypoxic) conditions, G. lamblia and E. histolytica, L. donovani (intracellular 
amastigote assay), T. b. brucei and C. difficile. To gain a clear understanding of the spectra of action, 
compounds were also screened against representative ESKAPE bacterial pathogens S. aureus (ATCC 
43300), E. coli (ATCC 25922), K. pneumoniae (ATCC 700603), A. baumannii (ATCC 19606) and P. 
aeruginosa (ATCC 27853) and fungal pathogens, C. albicans (ATCC 90028) and C. neoformans (H99 
type strain, ATCC 208821) at the Community for Open Antimicrobial Drug Discovery (CO-ADD).40 
The cytotoxicity against mammalian liver HepG2 and kidney HEK293 cell lines was also evaluated.
Gratifyingly, several compounds showed potent activity against M. tuberculosis, G. lamblia and T. b. 
brucei with the SAR discussed in detail below (Table 2). The N- and O-alkylated regioisomers had 
varying profiles, with the nitroimidazopyrazinones 17a-t consistently lacking activity against L. 
donovani, E. histolytica or C. difficile. However, nitroimidazopyrazine 18m was distinguished by its 
activity against E. histolytica (IC50 = 7.8 µM, Supporting Information, Table S5) and also G. lamblia 
(IC50 = 5.2 µM), despite no activity against M. tuberculosis compared to the imidazopyrazinone 
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derivative 17m. The screen against ESKAPE and fungal pathogens revealed that these compounds were 
selective for M. tuberculosis, G. lamblia and T. b. brucei as they were not active against the other 
organisms (MIC >32 µg/mL) (Supporting Information, Table S5). Importantly, the majority of the 
compounds were not cytotoxic at the highest concentration tested (CC50 >100 µM) against mammalian 
liver HepG2 and kidney HEK293 cell lines (CC50 > 100 µM) (Supporting Information, Table S5). 
However, compounds 17b (R1 = CH2Ph) and 17t (R1 = cyclohexyl) were moderately cytotoxic against 
mammalian liver and kidney cell lines (CC50 = 98–123 µM) compared to compounds 17a and 17c-s 
(CC50 >100 µM). Nitroimidazopyrazine derivatives 18i and 18m were also not cytotoxic against 
mammalian cell lines (CC50 >100 µM). This activity profile suggests a specific mechanism of action in 
M. tuberculosis, G. lamblia and T. b. brucei rather than a general non-specific toxic effect.
Nitroimidazopyrazinones 17b-i with a monosubstituted benzyl group at R1 displayed potent activity 
against M. tuberculosis (MICnormoxia = 0.06 –1 µg/mL) at levels up to 2-fold better than pretomanid 6 
(MICnormoxia = 0.25–0.5 µg/mL). There was a slight preference for substitution at the 3′ over the 2′ and 4′ 
positions of the phenyl group (cf. 17f-g with 17i and 17c-d). However, there was otherwise little 
electronic effect; both electron donating (17g, R1 = CH2(3-CH3-Ph)) and withdrawing substituents (17h, 
R1 = CH2(3-CF3-Ph)) had equal activity (MICnormoxia = 0.06 µg/mL). Poor solubility of 17j in the 
compound stock solutions was suspected to have contributed to the unexpected weak activity of this 
disubstituted-fluorine derivative against M. tuberculosis and the other organisms. Replacement of the 
phenyl group (17b) with a pyridyl moiety (17k) was unfavorable and resulted in a loss of activity against 
M. tuberculosis (17k MICnormoxia >32 µg/mL). A methyl substituent at the benzylic position (17l) was 
well tolerated (MICnormoxia = 0.5 µg/mL), but extension of the aromatic linkage with an ethyl bridge in 
the phenethyl derivatives (17m-n) resulted in a 16–32-fold loss of activity against M. tuberculosis, with 
bacteriostatic activity of MICnormoxia = 4-8 µg/mL compared to respective benzyl derivatives 17c-d with 
MICnormoxia = 0.125-0.5 µg/mL. None of the derivatives with polar groups at R1 (17o-s) had activity 
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against M. tuberculosis (MICnormoxia >32 µg/mL). Lastly, compound 17t with an aliphatic cyclohexyl 
group at R1 was also inactive (MICnormoxia >32 µg/mL), indicating a preference for an aromatic group 
rather than non-specific lipophilic group.
In general, compounds with activity against M. tuberculosis grown in normoxic conditions were also 
active against non-replicating M. tuberculosis under hypoxic conditions, although generally 2–16-fold 
less active. By comparison, isoniazid, a compound that inhibits cell wall synthesis in aerobically respiring 
M. tuberculosis (MIC = 0.04 µg/mL), did not inhibit growth in the hypoxic conditions (MIC >5 µg/mL). 
Metronidazole 1 was inactive (MIC >32 µg/mL) in this hypoxic-recovery assay, indicating the medium 
was not sufficiently anaerobic to show activity of 1 against M. tuberculosis.
The structure activity relationships observed for G. lamblia were similar to M. tuberculosis and several 
compounds (17c-d, 17f, 17l-n) were found to have improved activity (up to 4-fold) relative to 
metronidazole 1 (IC50 = 1.6 to 3.5 µM cf. 1 IC50 = 7.2 µM). Interestingly, an expanded range of the 
derivatives with lipophilic R1 groups had potent activity against G. lamblia. For example, 17m (R1 = 
CH2CH2(4-OCF3-Ph)) and 17n (R1 = CH2CH2(4-Me-Ph)) had similar activity to the benzyl-substituted 
analogs 17c-d against G. lamblia (IC50 = 1.6–3.2 µM vs 3.4–3.5 µM, respectively). In addition, the 
cyclohexyl derivative 17t was potent against G. lamblia at equivalent levels to the metronidazole 1 
control (17t G. lamblia IC50 = 5.2 µM).
 
There were also similar trends in the SAR observed against T. b. brucei although with a number of 
differences compared to M. tuberculosis and G. lamblia. For example, the activity of the benzyl series 
17b-i against T. b. brucei was sensitive to the particular nature of the benzyl substitution. For example, 
17c (R1 = CH2(4-OCF3-Ph)) and 17e (R1 = CH2(4-F-Ph)) were active against T. b. brucei (IC50 = 1.4 and 
2.9 µM, respectively), but compounds 17b (R1 = CH2Ph) and 17f (R1 = CH2(3-OCF3-Ph)) had reduced 
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activity at the highest concentrations tested (40 and 16 µM, respectively). Another difference observed 
for T. b. brucei was an increased tolerance for polar substituents at R1. For example, compounds with 
polar ethyl acetate (17o) or morpholino groups (17q-r) displayed moderate activity against T. b. brucei 
(IC50 = 2.9–6.5 µM), whereas against M. tuberculosis and G. lamblia these examples were essentially 
devoid of activity. The unsubstituted imidazopyrazinone compound 17a with H at R1 displayed some 
activity against T. b. brucei (97% inhibition at 40 µM) but was insufficiently active at 20 µM to determine 
an IC50 value. The cyclohexyl derivative 17t also had good activity against T. b. brucei (IC50 = 1.4 µM), 
similarly to G. lamblia. These examples demonstrate that it is possible to identify compounds with 
selective antiparasitic activity, although all compounds with M. tuberculosis activity tended to display 
some activity towards parasites. The selectivity observed for the particular organisms may be due to 
differences in the compound activation or uptake of the compounds and is an area of ongoing 
investigation.
Table 2. Activity of imidazopyrazinones and imidazopyrazinones with variation at R1, R2 = R3 = H.
Compound Antibacterial
MIC (µg/mL)
Antiparasitic
IC50 (µM) (pIC50 ± SE)d
No. Core R1
Molecular 
weight 
(g/mol) M. 
tuberculosisa
normoxia
M. 
tuberculosisa 
hypoxia
G. lambliab T. b. bruceic
Metronidazole 1 171.2 >32 >32 7.2 (5.1 ± 0.02) >40 (<4.4)
Pretomanid 6 359.3 0.25-0.5 1 3.0 (5.5 ± 0.02) 19 (4.7 ± 2.4)
17a A H 180.1 >32 >32 >25 (<4.6) 97% I @ 40 µM
17b A CH2Ph 270.2 0.5-1 4-8 5.0 (5.3 ± 0.05) 73%I @ 40 µM
17c A CH2(4-OCF3-Ph) 354.2 0.5 1-4 3.5 (5.5 ± 0.01) 1.4 (5.9 ± 0.08)
17d A CH2(4-CH3-Ph) 284.3 0.125 1-4 3.4 (5.5 ± 0.03) >40 (<4.4)
17e A CH2(4-F-Ph) 288.2 1 2 6.4 (5.2 ± 0.07) 2.9 (5.5 ± 0.41)
17f A CH2(3-OCF3-Ph) 354.2 0.125 0.5-2 1.7 (5.8 ± 0.03) 38% I @ 16 µM
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Compound Antibacterial
MIC (µg/mL)
Antiparasitic
IC50 (µM) (pIC50 ± SE)d
No. Core R1
Molecular 
weight 
(g/mol) M. 
tuberculosisa
normoxia
M. 
tuberculosisa 
hypoxia
G. lambliab T. b. bruceic
17g A CH2(3-CH3-Ph) 284.3 0.06 70-90% I @ 
0.125-8 
µg/mL
9.0 (5.0 ± 0.03) 5.4 (5.3 ± 0.23)
17h A CH2(3-CF3-Ph) 338.2 0.06 70-90% I @ 
0.06-16 
µg/mL
7.1 (5.1 ± 0.03) 5.3 (5.3 ± 0.18)
17i A CH2(2-OCF3-Ph) 354.2 1 8 8.2 (5.1 ± 0.03) 6.0 (5.2 ± 1.5)
17j A CH2(2,4-F-Ph) 306.2 16-32 >32 >50 (<4.3) >40 (<4.4)
17k A CH2(2-pyridyl) 271.2 >32 >32 14 (4.8 ± 0.05) 9.7 (5.0 ± 0.18)
17l A CHMe(4-F-Ph) 302.3 0.5 4-6.3 2.1 (5.7 ± 0.03) 94% I @ 40 µM
17m A CH2CH2(4-OCF3-
Ph)
368.3 8* (70%I) >32 1.6 (5.8 ± 0.04) 44%I @ 40 µM
17n A CH2CH2(4-CH3-
Ph)
298.3 4* (78%I) >32 3.2 (5.5 ± 0.04) >40 (<4.4)
17o A CH2CH2OAc 266.2 >32 >32 65 (4.2 ± 0.03) 6.5 (5.2 ± 0.22)
17p A CH2CH2OH 224.2 >32 >32 >50 (<4.3) 87%I @ 40 µM
17q A CH2CH2-
morpholine
293.3 >32 >32 ~50 (~4.3) 2.9 (5.5 ± 0.14)
17r A CH2CO-
morpholine
307.3 >32 >32 >50 (<4.3) 4.1 (5.4 ± 6.8)
17s A CH2CONH2 237.2 >32 >32 >50 (<4.3) >40 (<4.4)
17t A cyclohexyl 262.3 >32 >32 5.2 (5.3 ± 0.03) 1.4 (5.9 ± 0.13)
18i B CH2(2-OCF3-Ph) 354.2 >32 >32 12 (4.9 ± 0.05) >40 (<4.4)
18m B CH2CH2(4-OCF3-
Ph)
368.3 >32 >32 5.2 (5.3 ± 0.03) N.D
a H37Rv, M. tuberculosis-normoxia primary screen at 32 µg/mL n = 3, M. tuberculosis-hypoxia primary screen at 32 µg/mL n = 1–3, MIC-
normoxia/hypoxia of active compounds n = 3–6. Isoniazid control M. tuberculosis-normoxia MIC = 0.04 µg/mL, M. tuberculosis-hypoxia 
Page 19 of 90
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
MIC >5 µg/mL; b WB; c pentamidine control IC50 = 0.002 µM, diminazine aceturate IC50 = 0.062 µM, puromycin IC50 = 0.05 µM, n = 2; d 
the percentage inhibition (%I) at the highest concentration tested is reported for compounds that were not sufficiently active to determine 
an IC50. *Increasing concentrations of compound did not inhibit growth further.
Comparison of Bicyclic Antimicrobial Activity to Monocyclic 4- and 4(5)-Nitroimidazole 
Carboxamide Analogs
Given the activity of the bicyclic derivatives against M. tuberculosis, we screened a number of previously 
reported28 4-nitroimidazole carboxamides 28b-k and 4(5)-nitroimidazole carboxamides 16a, 16c, 16e 
and 16f, along with intermediates 16b and 16d prepared for this study, against M. tuberculosis under 
normoxic and hypoxic growth conditions. This would allow us to compare the SAR between the 
monocyclic and bicyclic series. Note that the 2-nitro group of the imidazopyrazinones occupies the 
equivalent position of the nitro group in the 4-nitroimidazole series (Figure 3). Interestingly, none of the 
4- or 4(5)- monocyclic nitroimidazoles tested were active against M. tuberculosis grown aerobically at 
32 µg/mL (Supporting Information, Table S6). Under hypoxic growth conditions, weak activity was 
observed for 28j and 16c (60-75% inhibition at 32 µg/mL), but this also correlated with increased 
cytotoxicity against the mammalian kidney cell line for these compounds (Supporting Information, Table 
S6). Therefore, the rigid, bicyclic nature of 17b-f appears necessary for antitubercular activity, especially 
against actively dividing M. tuberculosis cells, but is not essential for activity against other parasites. A 
comparison of the activity of the 4- and 4(5)- nitroimidazole carboxamide series with that of the bicyclic 
derivatives is summarized in Figure 3.
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Figure 3. 4-Nitroimidazoles 28b-k and 4(5)-nitroimidazole carboxamide 16b-f, compared to imidazopyrazinones 
17b-f.
Evaluation of Des-nitro Derivatives for Biological Activity
Two des-nitro derivatives 20b-c were prepared as negative control compounds, to confirm that the 
proposed mode of action relies on reduction of the nitro group. The des-nitro imidazopyrazinone 
derivatives 20b-c were tested for activity and indeed, were found to be inactive against M. tuberculosis, 
G. lamblia, T. b. brucei and E. histolytica (complete profiling results are detailed in the Supporting 
Information, Table S7). This result is consistent with the inactivity of a des-nitro pretomanid analog 9 
against M. tuberculosis under both aerobic and anaerobic growth (MIC >160 µM and >500 µM, 
respectively),41 and supports a critical role for the nitro group in the mechanism of action of 
nitroimidazopyrazinones.
SAR of Bicyclic Nitroimidazoles with Variation at R2 = Ph or CH3, R3 = H or CH3
Compounds 24a-e, 25a-m and 26a-i with R2 = Ph or CH3 and R3 = H or CH3 were evaluated for 
antiparasitic and antimicrobial in the same manner as described for 17a-t, 18i, 18m (Table 3). Both the 
R2 and R3 sites were found to influence activity against different pathogens to varying degrees. 
Interestingly, the modifications R2 and R3 on the imidazopyrazinone series was found to be particularly 
beneficial for activity against T. b. brucei. A number of imidazopyrazinones were active against T. b. 
brucei between 0.2 and 0.9 µM (24a-b, 25b, 25f, 25h, 26b, 26d, 26f and 26h). While some of the 
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pyrazine matched pairs generally lost activity, several compounds (24c, 25m, 26e, 26g and 26i) 
maintained activity in the 1.2–2.2 µM range. Furthermore, when R1 = CH2CH2OAc, compound 24b (R2 
= Ph) and 25b (R2 = CH3) showed 7.6–10-fold improvement compared to 17o (R2 = H). This benefit was 
also clear for the derivatives with benzyl substitutions at R1. For example, compound 17f (R1 = CH2(3-
OCF3-Ph), R2 = H, R3= H) showed incomplete inhibition at 16 µM, while the matched pairs 25j (R2 = 
CH3, R3= H) and 26f (R2 = CH3, R3= CH3) inhibited T. b. brucei at 1.1 and 0.40 µM, respectively. This 
last example also demonstrates a slight preference for methyl group substitutions at both R2 and R3 on 
the pyrazinone ring, as this resulted in activity that was consistently about two-fold improved.
The methyl and phenyl groups explored at R2 and R3 did not result in any overall improvement or loss 
of activity against G. lamblia, as the activity was generally in the same range. As observed for 
imidazopyrazine 18m, the expanded series of imidazopyrazine derivatives also had activity against G. 
lamblia. When R2 = Ph, R3 = H, the pyrazine derivatives 24c and 24e performed better than the 
pyrazinone analogs 24b and 24d against G. lamblia. However, similar activity was observed when R2 = 
CH3, R3 = H (e.g. matched pair 25h and 25i) and R2 = CH3, R3 = CH3 (e.g. matched pair 26d and 26e), 
although the pyrazine was slightly worse by two-fold for a few derivatives.
Activity against E. histolytica was also improved for the imidazopyrazinone series when R2= CH3 and 
R3= CH3. Both imidazopyrazinones (e.g 26b and 26f) and imidazopyrazines (e.g 26c and 26g) were 
active, with a slight preference for the imidazopyrazinone core. Despite this improvement, none of the 
derivatives had activity comparable to metronidazole 1, with the active derivatives having only moderate 
to weak activity (10–34 µM). This suggests distinct requirements for activity in E. histolytica compared 
to T. b. brucei and G. lamblia. Nonetheless, it is possible that further modification of the scaffold may 
lead to identification of an optimal “sweet spot” for activity against E. histolytica.
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Modifications explored at R2 and R3 were mostly detrimental for activity against M. tuberculosis. 
Activity against M. tuberculosis activity was abolished when R2 = CH3 or Ph and R3 = H. Consistent with 
the previous SAR study, all of the imidazopyrazines were found to be inactive (MIC >32 µg/mL). 
Nonetheless, activity was retained for three imidazopyrazinone examples (26b, 26d and 26f) when R2 = 
R3 = CH3 and R1 was a benzyl group. Compounds 26b, 26d and 26f also displayed activity against M. 
tuberculosis under hypoxic growth conditions and against G. lamblia, E. histolytica and T. b. brucei. 
These results indicate that it is possible to identify compounds with broad spectrum activity against both 
M. tuberculosis and parasites.
Continuing the trend previously observed for compounds 17a-t, 18i and 18m, none of the additional 
imidazopyrazin-ones/-es synthesized had appreciable activity against ESKAPE bacteria or fungal 
pathogens (MIC ≥ 32 µg/mL) (Supporting Information, Table S8). Both the nitroimidazopyrazinones 
and nitroimidazopyrazines series were also not cytotoxic against mammalian liver and kidney cell lines 
(CC50 >100 µM, 24d >75 µM due to compound limitations), except for 26f that displayed moderate 
cytotoxicity in both cell lines (CC50 = 26–80 µM) (Supporting Information, Table S8).
To summarize, the SAR of the R2, R3 sites was determined for both the nitroimidazopyrazinone and 
nitroimidazopyrazine series. Several compounds with potent activity against M. tuberculosis, G. lamblia 
and T. b. brucei were identified. Further work confirming the target/mode of action in M. tuberculosis, 
G. lamblia and T. b. brucei could aid in explaining the differences in activity. Additional studies to 
measure the reduction potential may provide insight into the differences in the activity between the 
nitroimidazopyrazinones and nitroimidazopyrazines.
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Table 3. SAR exploring the differences between the R2 and R3 groups for the imidazopyrazinone (core A) versus 
the imidazopyrazine (core B).
Compound Antibacterial
MIC (µg/mL)
Antiparasitic
IC50 (µM) (pIC50 ± SE)e
No. Core R1 R2 R3
Molecular 
weight 
(g/mol) M. 
tuberculosisa 
normoxia
M. 
tuberculosisa 
hypoxia
G. lambliab E. 
histolyticac
T. b 
bruceid
Metronidazole 1 171.2 >32 >32 7.2 (5.1 ± 
0.02)
4.3 (5.4 ± 
0.02)
>40 (<4.4)
Pretomanid 6 359.3 0.25-0.5 1 3.0 (5.5 ± 
0.02)
9.3 (5.0 ± 
0.03)
19 (4.7 ± 
2.4)
24a A H 256.2 >32 >32 10 (5.0 ± 
0.03)
>25 (<4.6) 0.22 (6.7 ± 
0.071)
24b A 342.3 >32 >32 11 (5.0 ± 
0.05)
34 (4.5 ± 
0.1)
0.86 (6.1 ± 
0.085)
24c B
CH2CH2OAc
342.3 >32 >32 1.9 (5.7 ± 
0.05)
>50 (<4.3) 1.5 (5.8 ± 
0.085)
24d A 300.3 >32 >32 38 (4.4 ± 
0.03)
>50 (<4.3) N.D.
24e B
CH2CH2OH
Ph H
300.3 >32 >32 5.2 (5.3 ± 
0.05)
>50 (<4.3) 1.1 (6.0 ± 
0.12)
25a A H 194.2 >32 >32 ~50 (~4.3) >50 (<4.3) 3.6 (5.4 ± 
0.20)
25b A 280.2 >32 >32 ~50 (~4.3) 41% I @ 
50 µM
0.65 (6.2 ± 
0.021)
25c B
CH2CH2OAc
280.2 >32 >32 21 (4.7 ± 
0.06)
42% I @ 
50 µM
>40 (<4.4)
25d A 238.2 >32 >32 >50 (<4.3) >50 (<4.3) 4.6 (5.3 ± 
0.092)
25e B
CH2CH2OH
CH3 H
238.2 >32 >32 80% I @ 
50 µM
>50 (<4.3) 56% I @ 
40 µM
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Compound Antibacterial
MIC (µg/mL)
Antiparasitic
IC50 (µM) (pIC50 ± SE)e
No. Core R1 R2 R3
Molecular 
weight 
(g/mol) M. 
tuberculosisa 
normoxia
M. 
tuberculosisa 
hypoxia
G. lambliab E. 
histolyticac
T. b 
bruceid
25f A 368.3 >32 >32 5.8 (5.2 ± 
0.04)
>50 (<4.3) 0.41 (5.4 ± 
0.057)
25g B
CH2(4-OCF3-
Ph)
368.3 >32 >32 7.4 (5.1 ± 
0.03)
9.5 (5 ± 
0.07)
>40 (<4.4)
25h A 298.3 >32 >32 4.4 (5.4 ± 
0.03)
10 (5.0 ± 
1.0)
0.56 (6.3 ± 
0.028)
25i B
CH2(4-CH3-
Ph)
298.3 N.D. N.D. 5.7 (5.2 ± 
0.03)
30 (4.5 ± 
0.1)
N.D.
25j A CH2(3-OCF3-
Ph)
368.3 >32 >32 2.8 (5.6 ± 
0.01)
16 (4.8 ± 
0.1)
1.1 (5.9 ± 
0.021)
25l A 368.3 >32 >32 3.3 (5.5 ± 
0.01)
9.1 (5 ± 
0.08)
2.1 (5.7 ± 
0.29)
25m B
CH2(2-OCF3-
Ph)
368.3 >32 >32 5.7 (5.2 ± 
0.02)
>50 (<4.3) 1.2 (5.9 ± 
0.13)
26a A H 208.2 >32 >32 ~50 (~4.3) >50 (<4.3) 2.6 (5.6 ± 
0.17)
26b A 382.3 1 4 4.2 (5.4 ± 
0.04)
10 (5 ± 
0.1)
0.24 (5.7 ± 
0.0071)
26c B
CH2(4-OCF3-
Ph)
382.3 >32 >32 8.6 (5.1 ± 
0.04)
17 (4.8 ± 
0.09)
10 (5.0 ± 
0.20)
26d A 312.3 2 4 5.2 (5.3 ± 
0.02)
33 (4.5 ± 
0.04)
0.25 (6.6 ± 
0.0071)
26e B
CH2(4-CH3-
Ph)
312.3 >32 >32 5.8 (5.2 ± 
0.02)
>50 (<4.3) 2.2 (5.6 ± 
0.31)
26f A CH2(3-OCF3-
Ph)
CH3 CH3
382.3 1 16-32 1.7 (5.8 ± 
0.01)
15 (4.8 ± 
0.03)
0.40 (6.4 ± 
0.0071)
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Compound Antibacterial
MIC (µg/mL)
Antiparasitic
IC50 (µM) (pIC50 ± SE)e
No. Core R1 R2 R3
Molecular 
weight 
(g/mol) M. 
tuberculosisa 
normoxia
M. 
tuberculosisa 
hypoxia
G. lambliab E. 
histolyticac
T. b 
bruceid
26g B 382.3 >32 >32 3.9 (5.4 ± 
0.01)
27 (4.6 ± 
0.02)
1.4 (5.9 ± 
0.24)
26h A 382.3 >32 >32 5.3 (5.3 ± 
0.03)
18 (4.7 ± 
0.02)
0.78 (6.1 ± 
0.090)
26i B
CH2(2-OCF3-
Ph)
382.3 >32 >32 >50 (<4.3) >50 (<4.3) 1.9 (5.7 ± 
0.27)
a H37Rv, M.tuberculosis-normoxia primary screen at 32 µg/mL n = 3, M. tuberculosis-hypoxia primary screen at 32 µg/mL n = 1–3, MIC-
normoxia/hypoxia of active compounds n = 3–6. Isoniazid control M. tuberculosis-normoxia MIC = 0.04 µg/mL, M. tuberculosis-hypoxia 
MIC >5 µg/mL; b WB; c HM1:IMSS; d pentamidine control IC50 = 0.002 µM, diminazine aceturate IC50 = 0.062 µM, puromycin IC50 = 0.05 
µM, n = 2; e the percentage inhibition (%I) at the highest concentration tested is reported for compounds that were not sufficiently active to 
determine an IC50.
Microsomal Stability, Plasma Stability and Plasma Protein Binding 
A set of ten compounds was selected for initial assessment of drug-like properties (microsomal stability, 
plasma stability and plasma protein binding (PPB)) based on their potency and structural diversity (Table 
4). It was also envisioned that these studies would provide clarity as to whether there was a clear benefit 
to either the nitroimidazopyrazinone or nitroimidazopyrazine series from the perspective of ADMET 
properties. Nitroimidazopyrazinones were stable in human liver microsomes (HLM) after 2 h of 
incubation, regardless of the structural differences in R1, R2 and R3. However, 18i, 25g and 26c from the 
nitroimidazopyrazine series only showed moderate stability in HLM, independent of differences at R1, 
R2, and R3, with 44-69% of compound remaining after 2 h (Table 4).
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To further understand how the metabolic stability could impact in vivo efficacy studies, metabolic 
stability was evaluated in CD-1 mouse liver microsomes (MLM) because the CD-1 mouse strain is 
intended to be used for future in vivo efficacy studies. As for HLM, the majority of the 
nitroimidazopyrazinones 17c-f, 17i and 25f displayed excellent stabilities toward MLM. However, one 
of the imidazopyrazinone analogs, 26b (R2 = R3 = CH3) showed significant degradation after 2 h, with 
only 3.6% of intact compound remaining (compared to 92% in HLM) (Table 4). Comparison of 25f with 
26b, which differ by the presence of a hydrogen or methyl group at R3 respectively, indicated that the 
methyl group at R3 was responsible for the high intrinsic clearance of 26b in MLM. 
Nitroimidazopyrazines, 18i, 25g and 26c were also not stable in MLM (<0.5–8% remaining), suggesting 
a metabolic liability of this series.
Compound stability in both human and mouse (CD-1) plasma was assessed for compounds 17c-f, 25f-g 
and 26b-c (Table 4). All of the examples had >90% of compound remaining after 2 h at 37 °C, similar 
to pretomanid 6. Therefore, both the nitroimidazopyrazinones and nitroimidazopyrazines series were 
stable in human and mouse plasma, despite the instability of nitroimidazopyrazines observed in liver 
microsomes.
Plasma protein binding affects compound bioavailability and tissue distribution in vivo. Therefore, to 
understand PPB for the nitroimidazopyrazines and nitroimidazopyrazines series, selected potent 
compounds (17c, 17e-f, 25f-g and 26b) were evaluated for PPB using the ultrafiltration method (Table 
4). Most of the tested compounds, except 17e (82% bound) had high PPB at >95%, which might limit 
the concentration of free compounds at the site of infection. However, as many approved and clinical 
drugs, including 6, tend to have high PPB, this parameter is not recommended to be optimized in early 
drug design.42
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Table 4. In vitro physicochemical properties for representative compounds.
Microsomal stability
(% remaining at 2 h)
Plasma stability
(% remaining at 2 h)
Compound Core R1 R2 R3
Human Mouse 
(CD-1)
Human Mouse (CD-
1)
Plasma 
protein 
binding 
(%)
Pretomanid 6 97 ± 5.0 92 ± 2.7 96 ± 6.9 96 ± 1.9 97 ± 1.1
17c A CH2(4-OCF3-Ph) >99 >99 >99 >99 98 ± 0.4
17d A CH2(4-CH3-Ph) 97 ± 1.1 96 ± 6.0 >99 >99 N.D
17e A CH2(4-F-Ph) 99 >99 98 ± 1.4 >99 82 ± 0.3
17f A CH2(3-OCF3-Ph) >99 >99 >99 97 ± 2.2 99 ± 0.2
17i A CH2(2-OCF3-Ph) >99 >99 N.D N.D N.D
18i B CH2(2-OCF3-Ph)
H H
51 ± 18 <0.5 N.D N.D N.D
25f A CH2(4-OCF3-Ph) >99 >99 92 ± 4.1 99 ± 4.8 98 ± 0.4
25g B CH2(4-OCF3-Ph)
CH3 H
69 ± 4.3 7.9 ± 4.0 94 ± 4.7 >99 >99
26b A CH2(4-OCF3-Ph) 92 ± 1.1 3.6 ± 0.1 97 ± 1.4 >99 99 ± 0.1
26c B CH2(4-OCF3-Ph)
CH3 CH3
44 ± 0.98 <0.5 >99 >99 N.D
Values are presented as mean of three replicates ± SD. N.D represents not determined. Microsome stability verapamil control = 2% (MLM), 
9% (HLM) remaining at 30 min; plasma stability eucatropine control = 28% (mouse), 21% (human) remaining at 2 h; plasma protein 
binding sulfamethoxazole control = 68% bound.
Caco-2 Intestinal Epithelium Permeability
An in vitro Caco-2 monolayer bidirectional assay was used to evaluate intestinal epithelium permeability 
and to predict the oral absorption of the nitroimidazopyrazinone series.43 Three derivatives (17c, 17f and 
26b) were selected based on potency against M. tuberculosis, G. lamblia and T. b. brucei and to permit 
direct comparison of R2 = R3 = H (17c) versus R2 = R3 = CH3 (26b). Pleasingly, compounds 17c, 17f and 
26b were highly permeable (Table 5). The apparent permeability coefficient (Papp) apical to basal (A to 
B) had values of >20 × 10-6 cm/s, similar to pretomanid 6 and propranolol, with the latter used as a 
positive control for high permeability. No metabolism of the compounds by Caco-2 cells was observed. 
This was evident from the high recovery of tested nitroimidazopyrazinones obtained in both directions, 
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similar to the control propranolol (A to B measured). Nitroimidazopyrazinones 17c, 17f and 26b and 6 
also showed a low efflux ratio of <2 (cf. digoxin efflux ratio >360 as it is a substrate for P-gp). Therefore, 
the tested bicyclic nitroimidazoles do not appear to be substrates of efflux transporters. These results 
suggest that 17c, 17f and 26b have desirable therapeutic properties and may display good oral absorption 
properties in vivo.
Table 5. Caco-2 permeability of selected analogs.
Papp (10-6 cm/s) Mean recovery (%)Compound Core R1 R2 R3
A to B B to A A to B A to B
Efflux ratio
Pretomanid 6* 29 22 81 101 0.74
Fenoterol 0.27 N.D 92 N.D N.D
Propranolol 21 N.D 70 N.D N.D
Digoxin <0.020 8.4 <72 88 >360
17c A CH2(4-OCF3-Ph) H H 25 22 83 97 0.88
17f A CH2(3-OCF3-Ph) H H 24 24 88 99 1.0
26b A CH2(4-OCF3-Ph) CH3 CH3 21 20 83 97 0.95
N.D represents not determined. * Comparable results with the literature.22
Kinetic Solubility
Compound solubility impacts in vivo absorption, efficacy and dosing and is thus an important parameter 
to optimize in drug development. For example, the recently approved TB drug, delamanid has limited 
solubility which requires twice daily dosing,44 and new bicyclic analogs with improved solubility would 
be of great interest. According to the generic criteria for hits and leads in infectious diseases identified 
by Japanese Global Health Innovative Technology (GHIT) Fund and its key partners, a lead should have 
acceptable physicochemical properties, with solubility at least >10 μM in phosphate-buffered saline pH 
7.4 (PBS).45
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The kinetic solubility of 48 compounds from the nitroimidazopyrazin-one/e libraries in water and PBS 
buffer (pH 7.4) was determined using LC-UV (Figure 4, for full data see Supporting Information, Table 
S9). The solubility of the derivatives varied over a wide range reflective of the different properties that 
the R1 side chain can impart. As anticipated, polar groups at R1 such as morpholine (17r: CH2CO-
morpholine, 17q: CH2CH2-morpholine), amide (17s: CH2CONH2) and alcohol groups (17p: 
CH2CH2OH) had >30-fold (∆LogS ~ 1.6 units) better solubility than benzyl derivatives (17b-j). The 
nitroimidazopyrazinones had equivalent or improved solubility relative to the nitroimidazopyrazine 
series and this is also reflected in their lower logP values. Encouragingly, when the solubility versus 
activity was compared, a number of compounds with antitrypanosomal activity (T. b. brucei IC50 ≤10 
µM) had good solubility at >100 μM (equivalent to logS >-4), including two potential hits 24b and 25b 
with IC50 <1 µM. The most potent compound 24a achieved moderate aqueous solubility (27 µM in water; 
17 µM in PBS), whereas 26b and 26d with comparable activity were poorly soluble (<10 µM, or logS 
<-5 in water and PBS) (Figure 4). These results demonstrate the potential to achieve desirable solubility 
and activity profile by modifying the R1 group of the bicyclic nitroimidazoles.
However, compounds with potent activity against M. tuberculosis, G. lamblia and E. histolytica generally 
had poor solubility. Most of the potent compounds against M. tuberculosis showed poor solubility with 
<10 μM in both water and PBS, which might require complicated formulations for in vivo efficacy. This 
indicates the importance of lipophilicity at the R1 side chain, which is potentially required for penetration 
of these molecules through the mycobacterial cell walls. Although changing R1 to CH2-pyridinyl 
decreased activity against M. tuberculosis, this derivative (17k) had significantly improved water 
solubility (176 µM in water; 184 µM in PBS) and decreased lipophilicity (∆LogP -0.94 units). Exploring 
other heterocyclic analogs may provide the desired balance of potency and solubility, which has been a 
successful strategy in the literature to identify analogs of pretomanid 6 with improved solubility.46,47
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Figure 4. Comparison of activity vs aqueous solubility data. Several compounds e.g. 25b active against T. b. 
brucei (in blue) had good solubility (>100 µM or logS > -4). Most of the potent compounds, e.g. 17h, against the 
other organisms displayed poor solubility (logS ≤ -5). Dashed lines represent the minimum and maximum range 
of solubility determined experimentally.
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Conclusion
In this study pretomanid 6 was shown to have potent activity against enteric pathogens including G. 
lamblia, E. histolytica and C. difficile. These results expand the current understanding of the spectrum of 
action of 6 from mycobacterium and Leishmania to include anaerobic protozoan parasites and an 
anaerobic Gram-positive bacterium. The in vitro activity of 6 against G. lamblia and E. histolytica at 
equivalent levels to metronidazole 1, suggests that this class of compounds and other subclasses of 
bicyclic nitroimidazoles could be a beneficial avenue to explore for the development of new 
nitroimidazole based therapeutics against these pathogens.
The activity of 6 against enteric pathogens inspired the synthesis and biological evaluation of two new 
bicyclic scaffolds; nitroimidazopyrazin-one/-es derived from the monocyclic 4(5)-nitroimidazole 
carboxamide framework previously reported. A modular synthetic approach enabled the exploration of 
bicyclic imidazopyrazinone derivatives with different substitutions at R1, R2 and R3, along with the 
isomeric O-alkylated nitroimidazopyrazine core scaffold. Through these studies, compounds with potent 
activity against M. tuberculosis, G. lamblia and T. b. brucei were identified. Several compounds also 
displayed moderate activity against E. histolytica. To our knowledge, this is the first example of a 
nitroimidazopyrazinone heterocyclic core with potent antiparasitic activity against M. tuberculosis under 
both normoxic and hypoxic growth conditions as well as promising antiparasitic activity against G. 
lamblia and T. b. brucei. The bicyclic core was essential for antitubercular activity.
This study highlights the potential to prepare new subclasses of bicyclic nitroimidazoles with varied ring 
systems to gain different selectivity profiles toward M. tuberculosis and a range of parasitic organisms. 
All of the compounds with M. tuberculosis activity also displayed activity towards at least some of the 
parasites tested. However, we showed that the activity profile of the series could be tuned towards 
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parasites away from M. tuberculosis, which may be relevant for treating parasitic diseases without 
inducing resistance in M. tuberculosis in co-exposed patients. For example, nitroimidazopyrazinones and 
nitroimidazopyrazines, particularly 24c, 24e (R2 = Ph) and 25h, 25j, 25l-m (R2 = CH3), were active 
against G. lamblia (IC50 = 1.9–5.7 µM, respectively) and T. b. brucei (IC50 = 0.56–2.1 µM, respectively) 
but not M. tuberculosis (MIC >32 µg/mL).
In general, these new subclasses displayed desirable therapeutic properties. Low cytotoxicity against 
mammalian cell lines was observed generally (CC50 >100 µM) for both series. In addition, many of the 
potent derivatives were stable in human and mouse liver microsomes, although the imidazopyrazine 
series was metabolized, particularly in MLM, and when R2 and R3 were methyl substituents. Selected 
derivatives also gave similar results to 6 in plasma stability, plasma protein binding and Caco-2 intestinal 
permeability assays. Like other early stage anti-tubercular leads including bicyclic nitroimidazoles, 
solubility was identified as an important parameter for future optimization. While a number of active 
compounds against T. b. brucei had moderate solubility, the most potent anti-tubercular compounds had 
poor aqueous kinetic solubility (<10 µM). Optimization of the R1, R2 and R3 sites, particularly the R1 
site, to arrive at more potent compounds, while maintaining desirable drug-like properties and improving 
the solubility will be explored in future studies.
This study lays the foundation for future work focused on determining and optimizing the efficacy of 
selected derivatives in in vivo models of M. tuberculosis, G. lamblia and T. b. brucei and understanding 
their mode of action in various microorganisms. These studies are expected to provide further insight 
into nitroimidazole activation and guide the development of bicyclic nitroimidazoles with therapeutic 
potential against both M. tuberculosis and a wide range of parasitic organisms.
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Experimental
General Information. Reagents and anhydrous solvents were used as received. Reactions requiring 
anhydrous conditions were performed under an inert atmosphere of nitrogen. Reactions were monitored 
by TLC or LCMS. Analytical TLC was performed on Merck TLC aluminum sheets pre-coated with 
Silica Gel 60 F-254 and compounds were visualized using UV254 lamp and potassium permanganate 
stain. Melting points were determined using a Gallenkamp melting point apparatus and are corrected to 
a standard curve of the measured and literature melting points of vanillin, acetyl salicylic acid, 3-
phenoxybenzoic acid and caffeine standards. Analytical LCMS was performed on a Shimadzu LCMS 
using 0.05% formic acid in water as solvent A and 0.05% formic acid in acetonitrile as solvent B. 
Standard conditions unless otherwise specified: Column Zorbax Eclipse XDB-Phenyl, 3.0×100mm, 3.5 
μ. Alternative column: Waters Atlantis T3, 3.0 × 100mm, 3 μ. Detection: PDA UV, ELSD and 
electrospray MS. Compounds were purified by MPLC (Biotage Isolera or Grace Reveleris X2 
chromatography systems) or by HPLC (Agilent Preparative HPLC 1260 Infinity Series). Commercially 
available cartridges were used for MPLC chromatography (Biotage SNAP cartridge HP-Silica 10 g, 25 
g or 50 g, Reveleris 4 g or 12 g Silica (40 µm) cartridge or Reveleris C18 Reversed-Phase 12 g cartridge). 
Column for HPLC: Agilent XDB Phenyl 5 µm, 30 x 100 mm. All products tested for biological activity 
were obtained in >95% purity as determined by HPLC using UV at 254 nm, ESIMS and ELSD detection. 
NMR data were collected and calibrated in DMSO-d6 or CDCl3 with 0.05% TMS at 298K on a Varian 
Unity 400 MHz or Bruker Avance-600 MHz spectrometer. Where appropriate, 1H-coupling constants 
were examined using resolution enhancement with MestReNova software. High resolution mass 
spectrometry (HRMS) was performed on a Bruker MicroTOF mass spectrometer using (+)-ESI 
calibrated to HCOONa. For compounds purified by reverse phase chromatography, the exact 
concentration of the compounds for assay was determined by the quantitative NMR integration 
‘PULCON’ experiment.48 These settings were used for all PULCON experiments: relaxation delay of 30 
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s, 8 scans, 2 dummy scans, 90° pulse and temperature at 298 K. The mass calculated from PULCON 
experiments was used to calculate the reaction percentage yields.
General Procedure A: Alkylation of imidazole and imidazopyrazinones
To a stirred solution of imidazole/imidazopyrazinone (1 eq) in anh. DMF (15–30 vol) was added K2CO3 
or Cs2CO3 (3 eq) followed by alkyl or benzyl halide (1.2–1.5 eq). The reaction was stirred at rt or heated 
in a microwave reactor at 80–180 °C for 15 min and monitored by LCMS. If necessary, an additional 
portion of alkylating agent (0.5–1.5 eq) was added and the reaction was heated at µW 120–180 °C for a 
further 15 min to consume the imidazole starting material. Work-up procedure A: the reaction was poured 
into H2O and extracted with EtOAc. The combined organic layers were washed with brine, dried over 
MgSO4 and filtered. Volatiles were removed in vacuo to give the crude product. Work-up procedure B: 
The reaction was poured into water, the precipitate collected by filtration, washed with water and dried 
in vacuo.
General Procedure B: Alkylation of imidazopyrazinones
To a stirred suspension of imidazopyrazinone (1 eq) in toluene (20 vol) was added Ag2CO3 (1.2 eq) 
followed by benzyl halide (2 eq). The reaction was heated at 80 °C overnight and monitored by LCMS. 
General aqueous work up: the reaction was poured into H2O and extracted with EtOAc. The combined 
organic layers were washed with brine, dried over MgSO4 and filtered. Volatiles were removed in vacuo 
to give the crude product.
General Procedure C: Ring closure to synthesize imidazopyrazinones
To a stirred solution of 4-nitroimidazole (1 eq) in 1,4-dioxane (10 vol) was added 2 M aq. HCl (10 vol). 
The reaction was heated at 120 °C for 30 min in the microwave. Work-up procedure A: The crystalline 
solid was collected by vacuum filtration. The precipitate was washed with water and dried in vacuo to 
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give a solid. Work-up procedure B: After heating the reaction, the volatiles were evaporated in vacuo to 
yield a crude material that was purified by recrystallization or chromatography.
General Procedure D: Deprotection of acetate protecting group
Anh. K2CO3 (1.5 eq) was added to a stirred suspension of ethyl acetate imidazopyrazinone (1 eq) in 
MeOH (20 vol). After 1 hr, volatiles were removed under a stream of N2. The solid was suspended with 
H2O, filtered, washed with water and dried under vacuum. Work-up procedure B: the reaction was 
acidified with a 5% solution of TFA in MeOH. The suspension was then concentrated onto C18 silica 
gel and purified by MPLC.
General Procedure E: Two step, one pot synthesis of imidazopyrazinones 
Alkylating agent (1.2–1.5 eq) was added slowly to a stirred suspension of 13a (1 eq), anh. K2CO3 (3 eq) 
in anh. DMF (15 vol). The reaction was stirred at rt until complete (10 min–5 h). 2M aq. HCl (15 vol), 
was then added slowly to control effervescence (CO2). The reaction was then stirred at rt (overnight to 4 
days), or for 22a heated with microwave irradiation until the cyclization was complete. The solid 
precipitate was collected by vacuum filtration, washed with water and MeOH and then dried in vacuo.
N-Benzyl-5-nitro-1H-imidazole-2-carboxamide; 16b
Prepared according to Jarrad et al.28 Amine: benzylamine (300 μL, 2.74 mmol). The crude material was 
purified over silica gel by MPLC (Biotage 20–100% EtOAc in pet. spirits gradient) to yield a colorless 
solid (399 mg, 71%). LCMS: Rt = 3.13 min, 99 A% @ 254 nm, [M - H]- = 245.0. 1H NMR (600 MHz, 
DMSO-d6) δ 14.31 (s, 1H), 9.45 (t, J = 6.4 Hz, 1H), 8.46 (s, 1H), 7.31 (d, J = 4.4 Hz, 4H), 7.27 – 7.20 
(m, 1H), 4.43 (d, J = 6.4 Hz, 2H). 13C NMR (150 MHz, DMSO-d6) δ 157.2, 146.8, 139.7, 139.1, 128.3, 
127.4, 126.9, 121.6, 42.3. HRMS (ESI): m/z calcd for C11H10N4NaO3 [M + Na]+, 269.0645; found, 
269.0639. 
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N-(4-Methylbenzyl)-5-nitro-1H-imidazole-2-carboxamide; 16d
Prepared according to Jarrad et al.28 Amine: 4-methylbenzylamine (155 μL, 1.37 mmol). The crude 
material was purified over silica gel by MPLC (Grace Reveleris X2, 20–100% EtOAc in pet. spirits 
gradient) to obtain a yellow solid (201 mg, 68%). LCMS: Rt = 3.27 min, 99 A% @ 254 nm, [M - H]- = 
259.0. 1H NMR (600 MHz, DMSO-d6) δ 14.30 (s, 1H), 9.37 (t, J = 6.4 Hz, 1H), 8.43 (s, 1H), 7.20 (d, J 
= 8.2 Hz, 2H), 7.11 (d, J = 7.8 Hz, 2H), 4.37 (d, J = 6.4 Hz, 2H), 2.26 (s, 3H). 13C NMR (150 MHz, 
DMSO-d6) δ 157.2, 146.8, 140.0, 136.1, 135.9, 128.8, 127.4, 121.8, 42.0, 20.7. HRMS (ESI): m/z calcd 
for C12H12N4NaO3 [M + Na]+, 283.0802; found, 283.0794. 
2-Nitroimidazo[1,2-a]pyrazin-8(7H)-one; 17a
To a stirred suspension of 19a (551 mg, 2.02 mmol) in H2O (11 mL) was added 5% aq. HCl (1.44 mL, 
1 eq). The reaction was refluxed for 4.5 h. The solvent was removed in vacuo. The crude product was 
purified by recrystallization (slurry equilibration with hot MeOH) to give fine off-white needles (241 
mg, 66%). Mp = 350 °C (decomposed). LCMS: Rt = 1.49 min, 99 A% @ 254 nm, [M + H]+ = 180.8. 1H 
NMR (600 MHz, DMSO-d6) δ 11.58 (s, 1H), 8.81 (s, 1H), 7.50 (d, J = 5.6 Hz, 1H), 7.07 (d, J = 5.7 Hz, 
1H). 13C NMR (150 MHz, DMSO-d6) δ 153.2, 147.6, 135.5, 119.8, 116.6, 107.1. The position of the 
nitro group was confirmed by HMBC and X-ray crystallography. X-ray diffraction data were collected 
on Oxford Diffraction Gemini Ultra dual source (Mo and Cu) CCD Diffractometer with Cu radiation (λ 
= 1.54184 Å), T = 190(2) K. Additional crystallographic data and HMBC data are available in the 
Supporting Information, Figure S1 and Tables S1-S3. HRMS (ESI): m/z calcd for C12H8N8NaO6 [2M + 
Na]+, 383.0459; found, 383.0454.
7-Benzyl-2-nitroimidazo[1,2-a]pyrazin-8(7H)-one; 17b
Compound 19b (150 mg, 0.414 mmol) was reacted according to general procedure C, work-up procedure 
B. The crude material was purified by recrystallization (hot slurry from DCM/MeOH) to yield a tan solid 
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(88 mg, 78%). Mp = 298–299 °C (decomposed). LCMS: Rt = 3.17 min, 99 A% @ 254 nm, [M + H]+ = 
271.0. 1H NMR (600 MHz, DMSO-d6) δ 8.81 (s, 1H), 7.60 (d, J = 5.9 Hz, 1H), 7.42 (d, J = 5.9 Hz, 1H), 
7.37 – 7.34 (m, 4H), 7.32 – 7.24 (m, 1H), 5.13 (s, 2H). 13C NMR (150 MHz, DMSO-d6) δ 152.8, 148.0, 
136.5, 135.2, 128.7, 127.8, 127.7, 123.6, 116.7, 107.4, 50.2. HRMS (ESI): m/z calcd for C13H10N4NaO3 
[M + Na]+, 293.0645; found, 293.0640.
2-Nitro-7-(4-(trifluoromethoxy)benzyl)imidazo[1,2-a]pyrazin-8(7H)-one; 17c
 Compound 19c (300 mg, 0.672 mmol) was reacted according to general procedure C, work-up procedure 
A, to yield a lemon yellow crystalline solid (207 mg, 87%). Mp = 264–266 °C (decomposed). LCMS: Rt 
= 3.47 min, 99 A% @ 254 nm, [M + H]+ = 355.0. 1H NMR (600 MHz, DMSO-d6) δ 8.82 (s, 1H), 7.62 
(d, J = 5.9 Hz, 1H), 7.52 – 7.47 (m, 2H), 7.46 (d, J = 5.9 Hz, 1H), 7.39 – 7.33 (m, 2H), 5.16 (s, 2H).13C 
NMR (150 MHz, DMSO-d6) δ 152.8, 148.0, 147.7, 136.0, 135.1, 129.7, 123.5, 121.2, 120.0 (q, J = 257.6 
Hz), 116.6, 107.5, 49.6. HRMS (ESI): m/z calcd for C14H9F3N4NaO4 [M + Na]+, 377.0468; found, 
377.0467.
7-(4-Methylbenzyl)-2-nitroimidazo[1,2-a]pyrazin-8(7H)-one; 17d
Compound 19d (100 mg, 0.266 mmol) was reacted according to general procedure C, work-up procedure 
B. The crude material was purified by recrystallization (slurry equilibration with hot DCM/MeOH) to 
yield a tan solid (53 mg, 70%). Mp = 311–312 °C (decomposed). LCMS: Rt = 3.30 min, 99 A% @ 254 
nm, [M + H]+ = 285.1. 1H NMR (600 MHz, DMSO-d6) δ 8.80 (s, 1H), 7.58 (d, J = 5.9 Hz, 1H), 7.39 (d, 
J = 5.9 Hz, 1H), 7.27 – 7.22 (m, 2H), 7.18 – 7.13 (m, 2H), 5.07 (s, 2H), 2.27 (s, 3H). 13C NMR (151 
MHz, DMSO-d6) δ 152.7, 148.0, 137.1, 135.1, 133.5, 129.2, 127.8, 123.5, 116.6, 107.4, 49.9, 20.7. 
HRMS (ESI): m/z calcd for C14H13N4O3 [M + H]+, 285.0982; found, 285.0973.
7-(4-Fluorobenzyl)-2-nitroimidazo[1,2-a]pyrazin-8(7H)-one; 17e
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Compound 19e (384 mg, 1.01 mmol) was reacted according to the general procedure C, work-up 
procedure A, to yield a yellow crystalline solid (249 mg, 86%). Mp = 297 °C (decomposed). LCMS: Rt 
= 3.23 min, 98 A% @ 254 nm, [M + H]+ = 289.0. 1H NMR (600 MHz, DMSO-d6) δ 8.81 (s, 1H), 7.60 
(d, J = 5.9 Hz, 1H), 7.44 (d, J = 5.9 Hz, 1H), 7.44 – 7.39 (m, 2H), 7.23 – 7.15 (m, 2H), 5.11 (s, 2H). 13C 
NMR (150 MHz, DMSO-d6) δ 161.7 (d, J = 243.9 Hz), 152.8, 148.0, 135.1, 132.7, 130.0 (d, J = 8.6 Hz), 
123.4, 116.6, 115.4 (d, J = 20.1 Hz), 107.4, 49.5. HRMS (ESI): m/z calcd for C13H9FN4NaO3 [M + Na]+, 
311.0551; found, 311.0551.
2-Nitro-7-(3-(trifluoromethoxy)benzyl)imidazo[1,2-a]pyrazin-8(7H)-one; 17f
Compound 19f (100 mg, 0.224 mmol) was reacted according to general procedure C, work-up procedure 
B. The crude material was purified by recrystallization (DCM/EtOH) with hot filtration to obtain a 
colorless pearlescent solid (33 mg, 42%). Mp = 230–231 °C (decomposed). LCMS: Rt = 3.45 min, 99 
A% @ 254 nm, [M + H]+ = 355.0. 1H NMR (600 MHz, DMSO-d6) δ 8.82 (s, 1H), 7.61 (d, J = 5.8 Hz, 
1H), 7.49 (t, J = 7.9 Hz, 1H), 7.45 (d, J = 5.9 Hz, 1H), 7.41 – 7.38 (m, 1H), 7.37 (ddd, J = 7.5, 1.6, 0.7 
Hz, 1H), 7.33 – 7.28 (m, 1H), 5.17 (s, 2H). 13C NMR (150 MHz, DMSO-d6) δ 152.9, 148.5, 148.0, 139.3, 
135.2, 130.7, 126.7, 123.5, 120.3, 120.2, 120.1 (q, J = 257.2 Hz), 116.7, 107.6, 49.8. HRMS (ESI): m/z 
calcd for C14H9F3N4NaO4 [M + Na]+, 377.0468; found, 377.0471.
7-(3-Methylbenzyl)-2-nitroimidazo[1,2-a]pyrazin-8(7H)-one; 17g
Compound 17a (70 mg, 0.389 mmol) was reacted according to general procedure B. The crude material 
contained imidazopyrazinone (major) and imidazopyrazine (minor) isomers in a ratio of 2:1 as detected 
by LC-MS (UV 254 nm). The crude was partially purified over silica gel by MPLC (Biotage Isolera, 0-
6% DCM/MeOH), then purified over C18-reversed phase silica (Grace Reveleris X2, A: H2O + 0.1% 
TFA, B: ACN + 0.1% TFA, 0–100% B) to yield imidazopyrazinone 17g as white powder (11 mg, 7%) 
and imidazopyrazine 18g as white powder (9 mg, 7%). Major isomer imidazopyrazinone 17g: LCMS: 
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Rt = 3.25 min, 99 A% @ 254 nm, [M+H]+  = 285.1. 1H NMR (600 MHz, DMSO-d6) δ 8.81 (s, 1H), 7.59 
(d, J = 5.9 Hz, 1H), 7.40 (d, J = 5.9 Hz, 1H), 7.24 (t, J = 7.6 Hz, 1H), 7.18 – 7.09 (m, 3H), 5.09 (s, 2H), 
2.28 (s 3H). 13C NMR (150 MHz, DMSO-d6) δ 152.7, 148.0, 137.9, 136.4, 135.1, 128.5, 128.4, 128.2, 
124.8, 123.5, 116.6, 107.3, 50.1, 20.9. HRMS (ESI): m/z calc for C14H12N4O3Na [M+Na]+: 307.0802, 
found 307.0800. Characterization data of 18g is listed below following Compounds 17a-t.
2-Nitro-7-(3-(trifluoromethyl)benzyl)imidazo[1,2-a]pyrazin-8(7H)-one; 17h
Compound 17a (70 mg, 0.389 mmol) was reacted with Cs2CO3 and 3-(trifluoromethyl)benzyl bromide 
(1.2 eq) according to general procedure A at µW 100 °C (15 min), work-up B. The crude material 
containing imidazopyrazinone (major) and imidazopyrazine (minor) isomers were detected in a ratio of 
10.1:1 by LC-MS (UV 254 nm). The crude material was purified over silica gel by MPLC (Biotage 
Isolera, 0-5% DCM/MeOH) to give final products imidazopyrazinone 17h as white powder (11 mg, 7%) 
and imidazopyrazine 18h as white powder (9 mg, 7%). Major isomer imidazopyrazinone 17h (cream 
powder, 72 mg, 55%): LCMS: Rt = 2.95 min, 99 A% @ 254 nm, [M+H]+  = 339.1; 1H NMR (600 MHz, 
DMSO-d6) δ 8.82 (s, 1H), 7.77 (d, J = 1.7 Hz, 1H), 7.67 (dd, J = 12.3, 7.4 Hz, 2H), 7.63 – 7.58 (m, 2H), 
7.48 (d, J = 5.9 Hz, 1H), 5.22 (s, 2H); 13C NMR (150 MHz, DMSO-d6) δ 152.9, 148.0, 137.9, 135.2, 
131.9, 129.7, 129.3 (q, J = 31.8 Hz), 124.5, 124.5, 124.1 (q, J = 272.2 Hz), 123.5, 116.7, 107.6, 
49.9.HRMS (ESI): m/z calc for C14H9F3N4O3Na [M+Na]+: 361.0519, found 361.0517. Characterization 
data of 18h is listed below following Compounds 17a-t.
2-Nitro-7-(2-(trifluoromethoxy)benzyl)imidazo[1,2-a]pyrazin-8(7H)-one; 17i 
Compound 17a (70 mg, 0.389 mmol) was reacted according to general procedure B. The crude material 
contained imidazopyrazinone (major) and imidazopyrazine (minor) isomers in a ratio of 1.9:1 as detected 
by LC-MS (UV 254 nm). The crude material was purified over C18-reversed phase silica (Grace 
Reveleris X2, A: H2O + 0.1% TFA, B: ACN + 0.1% TFA, 30–80% B) to give final product: Major 
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isomer imidazopyrazinone 17i (cream powder, 20 mg, 5%): LCMS: Rt = 2.95 min, 98 A% @ 254 nm, 
[M+H]+  = 355.1; 1H NMR (600 MHz, DMSO-d6) δ 8.84 (s, 1H), 7.63 (d, J = 5.9 Hz, 1H), 7.47 (ddd, J 
= 8.2, 7.1, 1.8 Hz, 1H), 7.42 (dt, J = 8.2, 1.6 Hz, 1H), 7.39 – 7.27 (m, 3H), 5.21 (s, 2H); 13C NMR (150 
MHz, DMSO-d6) δ 152.7, 148.0, 146.2, 135.1, 129.7, 129.5, 128.5, 127.6, 123.6, 120.5, 120.2 (q, J = 
257.1 Hz), 116.7, 107.5, 45.7. HRMS (ESI): m/z calc for C14H9F3N4O4Na [M+Na]+: 377.0468, found 
377.0469. Mixed fractions were combined and purified over silica gel by MPLC (Biotage Isolera, 0-6% 
DCM/MeOH) to yield minor isomer imidazopyrazine 18i (white powder, 11 mg, 3%). Characterization 
data of 18i is listed below following Compounds 17a-t.
7-(2,4-Difluorobenzyl)-2-nitroimidazo[1,2-a]pyrazin-8(7H)-one; 17j
Compound 17a (50 mg, 0.278 mmol) was reacted with Cs2CO3 and 2,4-difluorobenzyl bromide (1.2 eq) 
according to general procedure A at rt for 1 h, with work-up procedure B. The crude product was purified 
by recrystallization (slurry equilibration with hot DCM/EtOH) to yield the final product 
imidazopyrazinone 17j as a white powder (64 mg, 75%). LCMS: Rt  = 2.79 min, 99 A% @ 254 nm, 
[M+H]+  = 307.1; 1H NMR (600 MHz, DMSO-d6) δ 8.82 (s, 1H), 7.61 (d, J = 5.9 Hz, 1H), 7.43 (td, J = 
8.7, 6.5 Hz, 1H), 7.37 (d, J = 5.9 Hz, 1H), 7.30 (ddd, 10.7, 9.3, 2.6 Hz, 1H), 7.10 – 7.06 (m, 1H), 5.14 
(s, 2H); 13C NMR (150 MHz, DMSO-d6) δ 161.9 (dd, J = 246.9, 12.2 Hz), 160.3 (dd, J = 247.9, 12.2 
Hz), 152.7, 148.0, 135.0, 131.5 (dd, J = 10.3, 5.6 Hz), 123.6, 119.5 (dd, J = 15.2, 3.9 Hz), 116.7, 111.6 
(dd, J = 21.4, 3.2 Hz), 107.4, 104.0 (t, J = 25.7 Hz), 44.6 (d, J = 3.2 Hz). HRMS (ESI): m/z calc for 
C13H8F2N4O3Na [M+Na]+: 329.0457, found 329.0449.
2-Nitro-7-(pyridin-2-ylmethyl)imidazo[1,2-a]pyrazin-8(7H)-one.1TFA; 17k
Compound 19k (150 mg, 0.413 mmol) was reacted according to general procedure C, work-up procedure 
B. The crude material was purified over C18 silica gel by MPLC (Grace Reveleris X2, A: H2O + 0.1% 
TFA, B: ACN + 0.1% TFA, 5–30% B) to yield a colorless powder (88 mg, 56%). LCMS: Rt = 2.61 min, 
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99 A% @ 254 nm, [M + H]+ = 272.0. 1H NMR (600 MHz, DMSO-d6) δ 8.85 (s, 1H), 8.53 (dt, J = 4.8, 
1.4, 1H), 7.86 (td, J = 7.7, 1.8 Hz, 1H), 7.63 (d, J = 5.9 Hz, 1H), 7.44 (dd, J = 10.1, 6.9 Hz, 2H), 7.40 – 
7.34 (m, 1H), 5.26 (s, 2H). 13C NMR (150 MHz, DMSO-d6) δ 155.0, 152.8, 148.6, 148.0, 137.8, 135.1, 
124.6, 123.1, 122.1, 116.6, 107.1, 51.8. HRMS (ESI): m/z calcd for C12H9N5O3 [M + H]+, 272.0778; 
found, 272.0782. 
7-(1-(4-Fluorophenyl)ethyl)-2-nitroimidazo[1,2-a]pyrazin-8(7H)-one; 17l
Compound 19l (100 mg, 0.254 mmol) was reacted according to general procedure C, work-up procedure 
B. The crude material was purified by recrystallization (DCM/EtOH) with hot filtration to yield a 
colorless pearlescent solid (34 mg, 45%). Mp = 275–277 °C (decomposed). LCMS: Rt = 3.31 min, 99 
A% @ 254 nm, [M + H]+ = 303.0. 1H NMR (600 MHz, DMSO-d6) δ 8.77 (s, 1H), 7.57 (d, J = 6.1 Hz, 
1H), 7.47 – 7.41 (m, 2H), 7.24 – 7.19 (m, 3H), 6.15 (q, J = 7.1 Hz, 1H), 1.71 (d, J = 7.2 Hz, 3H). 13C 
NMR (150 MHz, DMSO-d6) δ 161.6 (d, J = 244.4 Hz), 152.6, 148.0, 136.2 (d, J = 2.90 Hz), 134.9, 129.3 
(d, J = 8.49 Hz), 119.8, 116.4, 115.5 (d, J = 21.3 Hz), 107.8, 51.6, 18.4. HRMS (ESI): m/z calcd for 
C14H11FN4NaO3 [M + Na]+, 325.0707; found, 325.0718.
2-Nitro-7-(4-(trifluoromethoxy)phenethyl)imidazo[1,2-a]pyrazin-8(7H)-one; 17m 
Imidazopyrazinone 17a (75 mg, 0.42 mmol), K2CO3 and 1-(2-bromoethyl)-4-(trifluoromethoxy)benzene 
(1.2 eq) were reacted according to general procedure A (µW 80 °C, 30 min). The crude material contained 
imidazopyrazinone (major) and imidazopyrazine (minor) isomers in a 10:1 ratio (1H NMR integration). 
The major imidazopyrazinone isomer 17m was obtained by purification of the crude residue over C18 
silica gel (Grace Reveleris X2, A: H2O + 0.1% TFA, B: ACN + 0.1% TFA, 40–100% B) to yield a cream 
solid (33 mg, 22%). Purification of mixed fractions over silica gel by MPLC (Grace Reveleris X2, 0–7% 
MeOH in DCM gradient) yielded an additional portion of imidazopyrazinone 17m as a cream solid (34 
mg, 22%) and the imidazopyrazine isomer 18m as a colorless solid (6 mg, 4%). Major isomer 
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imidazopyrazinone 17m: LCMS: Rt = 3.51 min, 99 A% @ 254 nm, 95 A% @ 200 nm, [M + H]+ = 
369.0. 1H NMR (600 MHz, DMSO-d6) δ 8.79 (s, 1H), 7.54 (d, J = 5.8 Hz, 1H), 7.41 – 7.35 (m, 2H), 7.29 
(d, J = 8.0 Hz, 2H), 7.27 (d, J = 5.9 Hz, 1H), 4.13 (t, J = 7.5 Hz, 2H), 3.00 (t, J = 7.5 Hz, 2H). 13C NMR 
(150 MHz, DMSO-d6) δ 152.6, 148.0, 147.0, 137.4, 135.0, 130.7, 123.6, 121.1, 120.1 (q, J = 257.1 Hz), 
116.5, 106.8, 48.6, 33.3. HRMS (ESI): m/z calcd for C15H12F3N4O4 [M + H]+, 369.0805; found, 
369.0814. Characterization data of 18m is listed below following Compounds 17a-t.
7-(4-Methylphenethyl)-2-nitroimidazo[1,2-a]pyrazin-8(7H)-one; 17n
Compound 19n (100 mg, 0.273 mmol) was reacted according to general procedure C, work-up procedure 
B. The crude material was purified by recrystallization (DCM/acetone) with hot filtration to yield a 
pearlescent tan solid (45 mg, 59%). Mp = 262–264 °C. LCMS: Rt = 3.38 min, 99 A% @ 254 nm, [M + 
H]+ = 299.1. 1H NMR (600 MHz, DMSO-d6) δ 8.78 (s, 1H), 7.52 (d, J = 5.8 Hz, 1H), 7.26 (d, J = 5.9 
Hz, 1H), 7.12 (d, J = 7.8 Hz, 2H), 7.09 (d, J = 7.8 Hz, 2H), 4.10 (dd, J = 8.4, 6.7 Hz, 2H), 2.92 (t, J = 7.5 
Hz, 2H), 2.25 (s, 3H). 13C NMR (150 MHz, DMSO-d6) δ 152.6, 148.0, 135.5, 135.0, 134.7, 129.1, 128.7, 
123.7, 116.4, 106.7, 49.0, 33.7, 20.7. HRMS (ESI): m/z calcd for C15H15N4O3 [M + H]+, 299.1139; found, 
299.1132.
2-(2-Nitro-8-oxoimidazo[1,2-a]pyrazin-7(8H)-yl)ethyl acetate; 17o
Imidazopyrazinone 17a (70 mg, 0.39 mmol), K2CO3 and 2-bromoethylacetate (1.5 eq) were reacted 
according to general procedure A (µW 80 °C, 30 min). Imidazopyrazinone isomer was detected as the 
major regioisomer, with a 10: 1 imidazopyrazinone:imidazopyrazine ratio, by LCMS (UV 254 nm). The 
reaction was poured into H2O (20 mL) and the precipitate filtered to yield a cream solid (72 mg, 69%). 
LCMS: Rt = 2.18 min, 99 A% @ 254 nm, [M + H]+ = 267.0. 1H NMR (600 MHz, DMSO-d6) δ 8.81 (s, 
1H), 7.58 (d, J = 5.9 Hz, 1H), 7.35 (d, J = 5.9 Hz, 1H), 4.33 – 4.27 (m, 2H), 4.19 – 4.14 (m, 2H), 1.97 
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(s, 3H). 13C NMR (150 MHz, DMSO-d6) δ 170.2, 152.8, 147.9, 134.9, 124.0, 116.5, 106.8, 61.3, 46.7, 
20.6. HRMS (ESI): m/z calcd for C10H10N4NaO5 [M + Na]+, 289.0543; found, 289.0545.
7-(2-Hydroxyethyl)-2-nitroimidazo[1,2-a]pyrazin-8(7H)-one; 17p
Compound 17o (45 mg, 0.17 mmol) was reacted according to general procedure D. The product was 
purified over C18 silica gel by MPLC (Grace Reveleris X2, A: H2O + 0.1% TFA, B: ACN + 0.1% TFA, 
5–22% B) to yield a pale lemon powder (18 mg, 45%). LCMS: Rt = 1.79 min, 99 A% @ 254 nm, [M + 
H]+ = 225.0. 1H NMR (600 MHz, DMSO-d6) δ 8.81 (s, 1H), 7.55 (d, J = 5.9 Hz, 1H), 7.29 (d, J = 5.8 
Hz, 1H), 4.90 (t, J = 5.7 Hz, 1H), 3.96 (t, J = 5.5 Hz, 2H), 3.66 (q, J = 5.6 Hz, 2H). 13C NMR (150 MHz, 
DMSO-d6) δ 152.8, 147.9, 135.1, 124.7, 116.3, 106.2, 58.4, 50.3. HRMS (ESI): m/z calcd for 
C8H8N4NaO4 [M + Na]+, 247.0438; found, 247.0435.
4-(2-(2-Nitro-8-oxoimidazo[1,2-a]pyrazin-7(8H)-yl)ethyl)morpholin-4-ium 2,2,2-trifluoroacetate; 
17q
Imidazopyrazinone 17a (75 mg, 0.42 mmol), 4-(2-chloroethyl)morpholine hydrochloride (1.5 eq), 
potassium iodide (0.06 eq), K2CO3 (3 eq) and anh. DMF (20 vol) were reacted according to general 
procedure A (µW 120 ºC, 15 min). To achieve conversion of the imidazopyrazinone starting material, 
further portions of potassium iodide (0.09 eq), 4-(2-chloroethyl)morpholine hydrochloride (1.5 eq) and 
anh. K2CO3 (1.5 eq) were added and the reaction heated in the microwave for a further 30 min at 120 ºC 
and then for 15 min at 150 ºC. The reaction was then evaporated to dryness to give crude material 
containing imidazopyrazinone (major) and imidazopyrazine (minor) isomers in a 13:1 ratio by LCMS 
(UV 254 nm). The crude solid was purified over C18 silica gel by MPLC (Grace Reveleris X2, A: H2O 
+ 0.1% TFA, B: ACN + 0.1% TFA, 5–15% B) to yield imidazopyrazinone 17q as a sticky solid (143 
mg, 84%) and imidazopyrazine 18q as a red residue (6 mg, 5%). Major isomer imidazopyrazinone 
17q: LCMS: Rt = 1.58 min, 99 A% @ 254 nm, [M + H]+ = 294.1. 1H NMR (600 MHz, DMSO-d6) δ 9.94 
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(br s, 1H), 8.86 (s, 1H), 7.67 (d, J = 5.9 Hz, 1H), 7.37 (d, J = 5.9 Hz, 1H), 4.31 (t, J = 6.2 Hz, 2H), 4.12 
– 3.89 (m, 2H), 3.85 – 3.32 (m, 4H), 3.29 – 2.95 (m, 2H), 2.92 – 2.60 (m, 2H). 13C NMR (150 MHz, 
DMSO-d6) δ 153.6, 148.0, 135.0, 123.2, 116.6, 107.7, 63.3, 54.3, 52.4, 51.5, 51.0, 41.4. HRMS (ESI): 
m/z calcd for C12H16N5O4 [M + H]+, 294.1197; found, 294.1197. Characterization data of 18q is listed 
below following Compounds 17a-t.
7-(2-Morpholino-2-oxoethyl)-2-nitroimidazo[1,2-a]pyrazin-8(7H)-one; 17r
Imidazopyrazinone 17a (75 mg, 0.42 mmol), K2CO3 and 4-(chloroacetyl)morpholine (1.2 eq), were 
reacted according to general procedure A (rt, 2.5 hr). The reaction volatiles were removed in vacuo. 
Imidazopyrazinone isomer was detected 99: 1 ratio by LCMS (UV 254 nm). A solid precipitated from 
ACN: (H2O + 0.1% TFA) mixture and was filtered. The solid was then washed with water (500 µL) and 
ACN (500 µL) and volatiles removed in vacuo to yield a tan pearlescent solid (80 mg, 63%). LCMS: Rt 
= 2.44 min, 99 A% @ 254 nm, [M + H]+ = 308.1. 1H NMR (600 MHz, DMSO-d6) δ 8.85 (s, 1H), 7.59 
(d, J = 5.9 Hz, 1H), 7.24 (d, J = 5.9 Hz, 1H), 4.89 (s, 2H), 3.66 (t, J = 4.8 Hz, 2H), 3.59 (t, J = 4.9 Hz, 
2H), 3.54 (t, J = 4.9 Hz, 2H), 3.45 (t, J = 4.9 Hz, 2H), 3.33 (s, 1H). 13C NMR (150 MHz, DMSO-d6) δ 
164.8, 152.8, 148.0, 134.8, 124.7, 116.8, 106.6, 66.0, 65.9, 48.7, 44.6, 41.9. HRMS (ESI): m/z calcd for 
C12H13N5NaO5 [M + Na]+, 330.0809; found, 330.0819.
2-(2-Nitro-8-oxoimidazo[1,2-a]pyrazin-7(8H)-yl)acetamide; 17s
Imidazopyrazinone 17a (75 mg, 0.42 mmol), K2CO3 and 2-bromoacetamide (1.2 eq) were reacted 
according to general procedure A at rt for 1.5 h. Imidazopyrazinone isomer was detected 32: 1 ratio by 
HPLC (UV 254 nm). The reaction was then filtered and the precipitate was washed with water (4 x 250 
µL) and MeOH (2 x 250 µL). The crude material was purified over C18 silica gel by MPLC (Grace 
Reveleris X2, A: H2O + 0.1% TFA, B: ACN + 0.1% TFA, 5–25% B) to yield a tan solid (5 mg, 4%). 
LCMS: Rt = 1.75 min, 99 A% @ 254 nm, [M + H]+ = 238.0. 1H NMR (600 MHz, DMSO-d6) δ 8.84 (s, 
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1H), 7.66 (br s, 1H), 7.57 (d, J = 5.9 Hz, 1H), 7.31 (br s, 1H), 7.30 (d, J = 5.8 Hz, 1H), 6.57 (s, 0.3H), 
4.52 (s, 2H). A broad singlet that was exchangeable with water was observed at 6.57 ppm integrating for 
0.3H. This has previously been observed for this class of compounds and is proposed to be due to 
protonation of the imidazopyrazinone core. 13C NMR (150 MHz, DMSO-d6) δ 168.2, 152.9, 148.0, 135.1, 
124.8, 116.6, 106.6, 49.9. HRMS (ESI): m/z calcd for C8H7N5NaO4 [M + Na]+, 260.0390; found, 
260.0392.
7-Cyclohexyl-2-nitroimidazo[1,2-a]pyrazin-8(7H)-one; 17t
Compound 19t (79 mg, 0.22 mmol) was reacted according to general procedure C, work-up procedure 
B. The crude material was purified by recrystallization (DCM/EtOH) to yield a cream colored crystalline 
solid (42 mg, 68%). Mp = 275–277 °C (decomposed). LCMS: Rt = 3.20 min, 99 A% @ 254 nm, [M + 
H]+ = 263.1. 1H NMR (600 MHz, DMSO-d6) δ 8.76 (s, 1H), 7.58 (d, J = 6.0 Hz, 1H), 7.43 (d, J = 6.1 
Hz, 1H), 4.66 (tt, J = 12.1, 3.8 Hz, 1H), 1.83 (d, J = 13.6 Hz, 2H), 1.74 (d, J = 12.0 Hz, 2H), 1.64 (qd, J 
= 12.3, 3.6 Hz, 3H), 1.41 (qt, J = 12.5, 3.4 Hz, 2H), 1.20 (qt, J = 12.5, 4.0 Hz, 1H). 13C NMR (150 MHz, 
DMSO-d6) δ 152.3, 148.0, 135.0, 119.8, 116.2, 107.1, 53.3, 30.8, 25.3, 24.7. HRMS (ESI): m/z calcd for 
C12H14N4NaO3 [M + Na]+, 285.0958; found, 285.0953.
8-((3-Methylbenzyl)oxy)-2-nitroimidazo[1,2-a]pyrazine; 18g 
Minor isomer imidazopyrazine 18g was isolated from 17g. LCMS: Rt = 3.58 min, 99 A% @ 254 nm, 
[M+H]+  = 285.1; 1H NMR (600 MHz, DMSO-d6) δ 9.02 (t, J = 1.8 Hz, 1H), 8.25 (dt, J = 3.8, 1.7 Hz, 
1H), 7.65 (dt, J = 4.0, 1.8 Hz, 1H), 7.36 – 7.28 (m, 3H), 7.20 (dd, J = 6.8, 3.5 Hz, 1H), 5.55 – 5.51 (m, 
2H), 3.42 (s, 1H), 2.34 (d, J = 2.1 Hz, 3H). Impurities were detected by 1H NMR and this compound was 
not subjected to biological evaluation.
2-Nitro-8-((3-(trifluoromethyl)benzyl)oxy)imidazo[1,2-a]pyrazine; 18h
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Minor isomer imidazopyrazine 18h was isolated from 17h. LCMS: Rt = 3.22 min, 99 A% @ 254 nm, 
[M+H]+  = 339.1; 1H NMR (600 MHz, CDCl3) δ 8.31 (s, 1H), 7.81 – 7.76 (m, 2H), 7.76 – 7.72 (m, 1H), 
7.63 – 7.58 (m, 2H), 7.54 – 7.48 (m, 1H), 5.67 (s, 2H). Impurities were detected by 1H NMR and this 
compound was not subjected to biological evaluation.
2-Nitro-8-((2-(trifluoromethoxy)benzyl)oxy)imidazo[1,2-a]pyrazine; 18i
Minor isomer imidazopyrazine 18i was isolated from 17i. LCMS: Rt = 3.25 min, 99 A% @ 254 nm, 
[M+H]+  = 355.1; 1H NMR (600 MHz, DMSO-d6) δ 9.04 (s, 1H), 8.27 (d, J = 4.7 Hz, 1H), 7.76 – 7.72 
(m, 1H), 7.66 (d, J = 4.7 Hz, 1H), 7.60 – 7.53 (m, 1H), 7.51 – 7.44 (m, 2H), 5.64 (s, 2H); 13C NMR (150 
MHz, DMSO-d6) δ 153.8, 148.2, 146.7, 131.2, 130.6, 130.1, 128.3, 128.0, 127.7, 120.7, 120.2 (q, J = 
258.3 Hz), 116.5, 115.0, 62.7.δ HRMS (ESI): m/z calc for C14H9F3N4O4Na [M+Na]+: 377.0468, found 
377.0470.
2-Nitro-8-(4-(trifluoromethoxy)phenethoxy)imidazo[1,2-a]pyrazine; 18m
Minor isomer imidazopyrazine 18m was isolated from 17m. LCMS: Rt = 3.76 min, 99 A% @ 254 nm, 
[M + H]+ = 369.1. 1H NMR (600 MHz, DMSO-d6) δ 9.01 (s, 1H), 8.22 (d, J = 4.7 Hz, 1H), 7.62 (d, J = 
4.7 Hz, 1H), 7.52 – 7.46 (m, 2H), 7.34 – 7.29 (m, 2H), 4.73 (t, J = 6.7 Hz, 2H), 3.20 (t, J = 6.7 Hz, 2H). 
13C NMR (150 MHz, DMSO-d6) δ 154.3, 148.2, 147.0, 137.7, 130.8, 128.2, 121.1, 120.1 (q, J = 256.2 
Hz), 116.0, 114.9, 67.1, 33.5. HRMS (ESI): m/z calcd for C15H12F3N4O4 [M + H]+, 369.0805; found, 
369.0799.
4-(2-((2-Nitroimidazo[1,2-a]pyrazin-8-yl)oxy)ethyl)morpholin-4-ium 2,2,2-trifluoroacetate; 18q
Minor isomer imidazopyrazine 18q was isolated from 17q. LCMS: Rt = 2.31 min, 97 A% @ 254 nm, 
[M + H]+ = 294.1. 1H NMR (600 MHz, DMSO-d6) δ 9.08 (s, 1H), 8.31 (d, J = 4.7 Hz, 1H), 7.67 (d, J = 
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4.7 Hz, 1H), 4.85 (br s, 2H), 4.27 – 3.02 (m, 10H). Impurities were detected in the 1H NMR analysis and 
therefore the compound was not subjected to biological analysis. 
1-(2,2-Diethoxyethyl)-4-nitro-1H-imidazole-2-carboxamide; 19a
Imidazole-2-carboxamide 16a (650 mg, 3.38 mmol) was reacted according to general procedure A with 
K2CO3, bromoacetaldehyde diethyl acetal (2 × 1.5 eq) at µW 180 °C (2 × 15 min). The crude material 
was triturated with pet. spirits (3 × 3 mL) and dried in vacuo to yield an orange solid (710 mg, 77%). 
LCMS: Rt = 3.04 min, 88 A% @ 254 nm, [M + H - EtOH]+ = 227.0. 1H NMR (400 MHz, CDCl3) δ 7.93 
(s, 1H), 7.93 (br s, 1H), 5.62 (br s, 1H), 4.73 (dd, J = 5.2, 4.5 Hz, 1H), 4.64 (d, J = 5.0 Hz, 2H), 3.75 (dq, 
J = 9.4, 7.1 Hz, 2H), 3.53 (dq, J = 9.4, 7.0 Hz, 2H), 1.19 (t, J = 7.0 Hz, 6H). 13C NMR (150 MHz, CDCl3) 
δ 159.5, 145.3, 136.2, 125.4, 100.5, 64.2, 51.8, 15.2. HRMS (ESI): m/z calcd for C10H16N4NaO5 [M + 
Na]+, 295.1013; found, 295.1010.
N-Benzyl-1-(2,2-diethoxyethyl)-4-nitro-1H-imidazole-2-carboxamide; 19b
Imidazole-2-carboxamide 16b (150 mg, 0.609 mmol) was reacted according to general procedure A with 
K2CO3 and bromoacetaldehyde diethyl acetal (1.5 eq, 2nd portion = 0.5 eq) at µW 150 °C (30 min, 
followed by 15 min) to yield a waxy yellow solid (219 mg, 99%). LCMS: Rt = 3.72 min, 97 A% @ 254 
nm, [M + H - EtOH]+ = 317.1. 1H NMR (400 MHz, CDCl3) δ 7.91 (s, 1H), 7.68 (t, J = 4.5 Hz, 1H), 7.40 
– 7.27 (m, 5H), 4.75 (dd, J = 5.3, 4.5 Hz, 1H), 4.68 (d, J = 4.8 Hz, 2H), 4.57 (d, J = 6.1 Hz, 2H), 3.75 
(dq, J = 9.0, 7.3 Hz, 2H), 3.54 (dq, J = 9.4, 6.9 Hz, 2H), 1.19 (t, J = 7.1 Hz, 6H). 13C NMR (150 MHz, 
CDCl3) δ 157.5, 145.2, 136.9, 136.8, 128.8, 128.0, 127.9, 125.2, 100.6, 64.2, 51.6, 43.4, 15.2. HRMS 
(ESI): m/z calcd for C17H22N4NaO5 [M + Na]+, 385.1482; found, 385.1480.
1-(2,2-Diethoxyethyl)-4-nitro-N-(4-(trifluoromethoxy)benzyl)-1H-imidazole-2-carboxamide; 19c
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Imidazole-2-carboxamide 16c (125 mg, 0.332 mmol) was reacted according to general procedure A with 
K2CO3 and bromoacetaldehyde diethyl acetal (2 × 1.5 eq) at µW 180 °C (2 × 15 min). The crude residue 
was purified over silica gel by MPLC (Biotage, 12–100% EtOAc in pet. spirits gradient) to yield a pale 
yellow waxy solid (112 mg, 76%). LCMS: Rt = 3.40 min, 99 A% @ 254 nm, [M - H]- = 445.0. 1H NMR 
(600 MHz, CDCl3) δ 7.92 (s, 1H), 7.75 (br t, 1H), 7.39 – 7.33 (m, 2H), 7.20 (m, 2H), 4.74 (dd, J = 5.1, 
4.5 Hz, 1H), 4.67 (d, J = 4.8 Hz, 2H), 4.57 (d, J = 6.2 Hz, 2H), 3.75 (dq, J = 9.4, 7.0 Hz, 2H), 3.53 (dq, 
J = 9.4, 7.0 Hz, 2H), 1.18 (t, J = 7.0 Hz, 6H). 13C NMR (150 MHz, CDCl3) δ 157.8, 148.9, 145.4, 136.8, 
136.0, 129.5, 125.4, 121.5, 120.6 (q, J = 256.5 Hz), 100.7, 64.3, 51.7, 42.7, 15.3. HRMS (ESI): m/z calcd 
for C18H21F3N4NaO6 [M + Na]+, 469.1305; found, 469.1316.
1-(2,2-Diethoxyethyl)-N-(4-methylbenzyl)-4-nitro-1H-imidazole-2-carboxamide; 19d
Imidazole-2-carboxamide 16d (75 mg, 0.29 mmol) was reacted according to general procedure A with 
K2CO3 and bromoacetaldehyde diethyl acetal (2 × 1.5 eq) at µW 150 °C (2 × 30 min) to yield a yellow 
oil which was used without further purification (116 mg with 43 mol% residual DMF by 1H NMR, 98%). 
LCMS: Rt = 3.80 min, 97 A% @ 254 nm, [M + H - EtOH]+ = 331.1. 1H NMR (600 MHz, CDCl3) δ 7.92 
(s, 1H), 7.67 (d, J = 5.7 Hz, 1H), 7.25 – 7.19 (m, 2H), 7.19 – 7.14 (m, 2H), 4.76 (t, J = 4.9 Hz, 1H), 4.68 
(d, J = 4.9 Hz, 2H), 4.54 (d, J = 6.1 Hz, 2H), 3.77 (dq, J = 9.4, 7.0 Hz, 2H), 3.55 (dq, J = 9.4, 7.0 Hz, 
2H), 2.35 (s, 3H), 1.19 (t, J = 7.0 Hz, 5H). 13C NMR (151 MHz, CDCl3) δ 157.5, 145.2, 137.6, 136.9, 
133.9, 129.5, 128.0, 125.2, 100.6, 64.2, 51.6, 43.2, 21.1, 15.2. HRMS (ESI): m/z calcd for C18H24N4NaO5 
[M + Na]+, 399.1639; found, 399.1643.
1-(2,2-Diethoxyethyl)-N-(4-fluorobenzyl)-4-nitro-1H-imidazole-2-carboxamide; 19e
Imidazole-2-carboxamide 16e (311 mg, 1.18 mmol) was reacted according to general procedure A with 
K2CO3 and bromoacetaldehyde diethyl acetal (2 × 1.5 eq) at µW 180 °C (2 × 15 min). The crude residue 
was purified over silica gel by MPLC (Biotage, 10–60% EtOAc in pet. spirits gradient) to yield a pale 
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yellow oil (411 mg, 92%). LCMS: Rt = 3.76 min, 99 A% @ 254 nm, [M + H - EtOH]+ = 335.0. 1H NMR 
(400 MHz, CDCl3) δ 7.91 (s, 1H), 7.70 (br s, 1H), 7.35 – 7.27 (m, 2H), 7.09 – 6.98 (m, 2H), 4.74 (dd, J 
= 5.2, 4.4 Hz, 1H), 4.67 (d, J = 4.8 Hz, 2H), 4.60 – 4.50 (m, 2H), 3.75 (dq, J = 9.4, 7.0 Hz, 2H), 3.54 (dq, 
J = 9.4, 7.0 Hz, 2H), 1.18 (t, J = 7.0 Hz, 6H). 13C NMR (150 MHz, CDCl3) δ 162.4 (d, J = 245.19 Hz), 
157.6, 145.3, 136.8, 132.8 (d, J = 3.8 Hz), 129.7 (d, J = 8.1 Hz), 125.2, 115.7 (d, J = 21.6 Hz), 100.6, 
64.2, 51.6, 42.7, 15.2. HRMS (ESI): m/z calcd for C17H21F1N4NaO5 [M + Na]+, 403.1388; found, 
403.1389.
1-(2,2-Diethoxyethyl)-4-nitro-N-(3-(trifluoromethoxy)benzyl)-1H-imidazole-2-carboxamide; 19f
Imidazole-2-carboxamide 16f (75 mg, 0.23 mmol) was reacted according to general procedure A with 
K2CO3 and bromoacetaldehyde diethyl acetal (2 × 1.5 eq) at µW 150 °C (2 × 30 min) to yield an orange 
solid which was used without further purification (108 mg, quant.). LCMS: Rt = 3.88 min, 95 A% @ 254 
nm, [M + H - EtOH]+ = 401.1. 1H NMR (600 MHz, CDCl3) δ 7.94 (s, 1H), 7.81 (t, J = 6.1 Hz, 1H), 7.39 
(t, J = 7.9 Hz, 1H), 7.30 – 7.24 (m, 1H), 7.21 – 7.14 (m, 2H), 4.75 (dd, J = 5.2, 4.5 Hz, 1H), 4.69 (d, J = 
4.8 Hz, 2H), 4.60 (d, J = 6.3 Hz, 2H), 3.76 (dq, J = 9.4, 7.1 Hz, 2H), 3.54 (dq, J = 9.4, 7.0 Hz, 2H), 1.19 
(t, J = 7.0 Hz, 6H). 13C NMR (150 MHz, CDCl3) δ 157.7, 149.5, 145.2, 139.5, 136.6, 130.2, 126.1, 125.3, 
120.4 (q, J = 260.9 Hz), 120.4, 120.2, 100.5, 64.2, 51.6, 42.7, 15.1. HRMS (ESI): m/z calcd for 
C18H21F3N4NaO6 [M + Na]+, 469.1305; found, 469.1306.
1-(2,2-Diethoxyethyl)-4-nitro-N-(pyridin-2-ylmethyl)-1H-imidazole-2-carboxamide; 19k
Imidazole-2-carboxamide 16k (150 mg, 0.607 mmol) was reacted according to general procedure A with 
K2CO3 and bromoacetaldehyde diethyl acetal (1.5 eq, 2nd portion = 0.5 eq) at µW 150 °C (30 min, 
followed by 15 min) to yield a red oil which was used without further purification (153 mg, 69%). LCMS: 
Rt = 3.13 min, 97 A% @ 254 nm, [M + H - EtOH]+ = 318.1. 1H NMR (600 MHz, DMSO-d6) δ 9.41 (t, 
J = 6.1 Hz, 1H), 8.52 (s, 1H), 8.51 (ddd, J = 4.7, 1.7, 1.0 Hz, 1H), 7.76 (td, J = 7.7, 1.8 Hz, 1H), 7.32 (d, 
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J = 8.3 Hz, 1H), 7.27 (ddd, J = 7.6, 4.9, 1.1 Hz, 1H), 4.79 (t, J = 5.2 Hz, 1H), 4.60 (d, J = 5.2 Hz, 2H), 
4.53 (d, J = 6.1 Hz, 2H), 3.61 (dq, J = 9.7, 7.0 Hz, 2H), 3.41 (dq, J = 9.7, 7.0 Hz, 2H), 1.02 (t, J = 7.0 
Hz, 6H). 13C NMR (150 MHz, DMSO-d6) δ 157.9, 157.7, 148.9, 144.4, 137.7, 136.7, 126.4, 122.2, 120.9, 
100.0, 62.8, 50.3, 44.1, 15.1. HRMS (ESI): m/z calcd for C16H22N5O5 [M + H]+, 364.1615; found, 
364.1622.
1-(2,2-Diethoxyethyl)-N-(1-(4-fluorophenyl)ethyl)-4-nitro-1H-imidazole-2-carboxamide; 19l
Imidazole-2-carboxamide 16l (75 mg, 0.27 mmol) was reacted according to general procedure A with 
K2CO3 and bromoacetaldehyde diethyl acetal (1.5 eq, 2nd portion = 1 eq) at µW 150 °C (2 × 30 min) to 
yield a yellow oil (113 mg, quant) which was used without further purification. LCMS: Rt = 3.80 min, 
97 A% @ 254 nm, [M + H - EtOH]+ = 349.1. 1H NMR (600 MHz, CDCl3) δ 7.92 (s, 1H), 7.60 (d, J = 
8.2 Hz, 1H), 7.37 – 7.31 (m, 2H), 7.08 – 7.01 (m, 2H), 5.20 (p, J = 7.2 Hz, 1H), 4.74 – 4.66 (m, 2H), 
4.65 – 4.56 (m, 1H), 3.77 – 3.69 (m, 2H), 3.52 (dq, J = 9.4, 7.0 Hz, 2H), 1.60 (d, J = 7.0 Hz, 3H), 1.17 
(dt, J = 12.1, 7.0 Hz, 6H). 13C NMR (150 MHz, CDCl3) δ 162.1 (d, J = 245.3 Hz), 156.8, 145.2, 138.1 
(d, J = 3.0 Hz), 136.8, 127.8 (d, J = 8.2 Hz), 125.3, 115.6 (d, J = 21.8 Hz), 100.5, 64.1, 51.6, 48.5, 21.9, 
15.1. HRMS (ESI): m/z calcd for C18H23FN4NaO5 [M + Na]+, 417.1545; found, 417.1537.
1-(2,2-Diethoxyethyl)-N-(4-methylphenethyl)-4-nitro-1H-imidazole-2-carboxamide; 19n
Imidazole-2-carboxamide 16n (75 mg, 0.27 mmol) was reacted according to general procedure A with 
K2CO3 and bromoacetaldehyde diethyl acetal (2 × 1.5 eq) at µW 150 °C (2 × 30 min) to yield a yellow 
oil which was used without further purification (112 mg, quant.). LCMS: Rt = 3.85 min, 98 A% @ 254 
nm, [M + H - EtOH]+ = 345.1. 1H NMR (600 MHz, CDCl3) δ 7.90 (s, 1H), 7.46 (t, J = 6.2 Hz, 1H), 7.19 
– 7.03 (m, 4H), 4.72 (t, J = 4.9 Hz, 1H), 4.64 (d, J = 4.9 Hz, 2H), 3.76 (dq, J = 9.4, 7.0 Hz, 2H), 3.64 (dt, 
J = 7.7, 6.5 Hz, 2H), 3.53 (dq, J = 9.4, 7.0 Hz, 2H), 2.91 – 2.85 (m, 2H), 2.34 (s, 3H), 1.19 (t, J = 7.0 Hz, 
6H). 13C NMR (150 MHz, CDCl3) δ 157.6, 145.1, 136.9, 136.2, 135.1, 129.4, 128.6, 125.1, 100.7, 64.2, 
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51.6, 40.8, 35.3, 21.0, 15.2. HRMS (ESI): m/z calcd for C19H26N4NaO5 [M + Na]+, 413.1795; found, 
413.1797.
N-Cyclohexyl-1-(2,2-diethoxyethyl)-4-nitro-1H-imidazole-2-carboxamide; 19t
Imidazole-2-carboxamide 16t (75 mg, 0.31 mmol) was reacted according to general procedure A with 
K2CO3 and bromoacetaldehyde diethyl acetal (1.5 eq, 2nd portion = 1 eq) at µW 150 °C (2 × 30 min) to 
yield an orange solid (107 mg, 96%) which was used without further purification. LCMS: Rt = 3.78 min, 
97 A% @ 254 nm, [M + H]+ = 309.1. 1H NMR (600 MHz, CDCl3) δ 7.90 (s, 1H), 7.24 (d, J = 8.5 Hz, 
1H), 4.75 (t, J = 5.0 Hz, 1H), 4.65 (d, J = 5.0 Hz, 2H), 3.88 (tdt, J = 11.9, 8.2, 3.9 Hz, 1H), 3.76 (dq, J = 
9.3, 7.1 Hz, 2H), 3.54 (dq, J = 9.3, 7.0 Hz, 2H), 2.02 – 1.96 (m, 2H), 1.83 – 1.77 (m, 2H), 1.72 – 1.62 
(m, 1H), 1.44 – 1.35 (m, 2H), 1.35 – 1.25 (m, 3H), 1.19 (t, J = 7.0 Hz, 6H). 13C NMR (150 MHz, CDCl3) 
δ 156.8, 145.1, 137.2, 125.1, 100.7, 64.2, 51.7, 48.8, 32.9, 25.3, 25.0, 15.2. HRMS (ESI): m/z calcd for 
C16H26N4NaO5 [M + Na]+, 377.1795; found, 377.1794.
Imidazo[1,2-a]pyrazin-8(7H)-one; 20a
To a stirred suspension of imidazole 23a (168 mg, 0.741 mmol) in H2O (20 vol.) was added 5% w/v HCl 
(530 µL, 1 eq). The solution was heated to reflux for 2 h, cooled to rt and concentrated in vacuo to 
dryness. The solid was purified by recrystallization (slurry equilibration with hot MeOH) to yield beige 
crystals (50 mg, 50%). Mp = 307–308 °C (decomposed). LCMS (Waters Atlantis): Rt = 1.75 min, 99 
A% @ 254 nm, [M + H]+ = 136.1 1H NMR (400 MHz, DMSO-d6) δ 8.20 (d, J = 1.7 Hz, 1H), 8.01 (d, J 
= 1.7 Hz, 1H), 7.75 (d, J = 5.6 Hz, 1H), 7.23 (t, J = 5.6 Hz, 1H). 13C NMR (150 MHz, DMSO-d6) δ 
151.3, 135.1, 126.3, 119.7, 118.3, 107.2. HRMS calcd for C12H10N6NaO2 [2M + Na]+, 293.0757; found, 
293.0764. The proton spectra was consistent with literature.35
7-Benzylimidazo[1,2-a]pyrazin-8(7H)-one; 20b
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To a stirred suspension of compound 23b (120 mg, 0.378 mmol) in H2O (20 vol.) was added 5% aq. HCl 
(270 µL, 1 eq). The reaction was heated at 80 °C for 3 days before further addition of 5% aq. HCl (135 
µL, 0.5 eq). The reaction mixture was then washed with EtOAc (3 × 5 mL followed by 3 × 10 mL). The 
aqueous layer was then evaporated to dryness. The crude material was purified over C18 silica gel by 
MPLC (Grace Reveleris X2. A: H2O + 0.1% TFA, B: ACN + 0.1% TFA, 10–30% B) to yield a colorless 
solid (47 mg, 39%). LCMS: Rt = 2.14 min, 98 A% @ 254 nm, [M + H]+ = 226.0. 1H NMR (600 MHz, 
DMSO-d6) δ 7.93 (d, J = 1.2 Hz, 1H), 7.69 – 7.65 (m, 2H), 7.40 – 7.27 (m, 6H), 5.14 (s, 2H). 13C NMR 
(151 MHz, DMSO-d6) δ 152.1, 136.7, 136.0, 130.3, 128.5, 127.6, 127.6, 121.6, 117.8, 107.4, 49.8. 
HRMS (ESI): m/z calcd for C13H11N3NaO [M + Na]+, 248.0794; found, 249.0799.
7-(4-Fluorobenzyl)imidazo[1,2-a]pyrazin-8(7H)-one; 20c
Imidazopyrazinone 20a (100 mg, 0.740 mmol), K2CO3 and 4-fluorobenzyl bromide (1.2 eq), were 
reacted according to general procedure A at rt for 45 min. The imidazopyrazinone regioisomer was 
detected as the preferred isomer (24: 1 ratio) by HPLC (UV 254 nm). The crude material was purified 
by recrystallization (EtOH) to yield a colorless solid (34 mg, 19%). Mp = 168–169 °C. LCMS: Rt = 2.94 
min, 99 A% @ 254 nm, [M + H]+ = 244.1. 1H NMR (400 MHz, DMSO-d6) δ 7.84 – 7.78 (m, 1H), 7.61 
(d, J = 5.8 Hz, 1H), 7.52 – 7.46 (m, 1H), 7.45 – 7.36 (m, 2H), 7.24 (d, J = 5.9 Hz, 1H), 7.22 – 7.12 (m, 
2H), 5.09 (s, 2H). 13C NMR (150 MHz, DMSO-d6) δ 161.6 (d, J = 243.2 Hz), 153.0, 137.0, 133.4 (d, J 
= 3.0 Hz), 132.7, 129.9 (d, J = 8.5 Hz), 120.4, 117.6, 115.4 (d, J = 21.7 Hz), 107.5, 49.1. HRMS (ESI): 
m/z calcd for C13H11FN3O [M + H]+, 244.0881; found, 244.0884.
N-(Benzyl)-1H-imidazole-2-carboxamide; 22b 
1H-Imidazole-2-carboxylic acid 21a (1.08 g, 9.60 mmol) was refluxed in SOCl2 (10 mL) under N2 for 
22 h. Volatiles were removed in vacuo and residual SOCl2 was removed by co-evaporation with toluene 
to give the crude acid chloride intermediate. Benzylamine (478 μL, 4.38 mmol) was added drop wise to 
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acid chloride (476 mg, 3.65 mmol) suspended in anh. THF (13 mL) under an atmosphere of N2. The light 
brown precipitate was filtered and washed with THF to yield a tan solid (685 mg, 79%) that was used 
without further purification. LCMS: Rt = 2.68 min, 99 A% @ 254 nm, [M + H]
+ = 202.1. 1H NMR (600 
MHz, CDCl3) δ 8.97 (t, J = 5.7 Hz, 1H), 7.49–7.04 (m, 7H), 4.43 (d, J = 6.2 Hz, 2H). 13C NMR (150 
MHz, CDCl3) δ 158.3, 140.9, 139.5, 134.0, 128.1, 127.1, 126.6, 119.6 (br), 41.8. 
1-(2,2-Diethoxyethyl)-1H-imidazole-2-carboxamide; 23a
Imidazole-2-carboxamide 22a (650 mg, 5.85 mmol) was reacted according to general procedure A with 
K2CO3, bromoacetaldehyde diethyl acetal (2 × 1.5 eq) at µW 120 °C (2 × 15 min) to yield a yellow solid 
that was used without further purification (1.08 g, 81%). LCMS: Rt = 2.65 min, 99 A% @ 254 nm, [M 
+ H- EtOH]+ = 182.1. 1H NMR (400 MHz, CDCl3) δ 7.23 (br s, 1H), 7.12 (d, J = 1.1 Hz, 1H), 7.01 (d, J 
= 1.1 Hz, 1H), 5.33 (br s, 1H), 4.84 – 4.60 (m, 1H), 4.53 (d, J = 5.3 Hz, 2H), 3.73 (dq, J = 9.4, 7.0 Hz, 
2H), 3.48 (dq, J = 9.4, 7.0 Hz, 2H), 1.16 (t, J = 7.0 Hz, 6H). 13C NMR (150 MHz, CDCl3) δ 161.1, 137.8, 
127.6, 126.7, 101.8, 64.0, 51.0, 15.2. NMR data was consistent with literature.35 
N-Benzyl-1-(2,2-diethoxyethyl)-1H-imidazole-2-carboxamide; 23b
Imidazole-2-carboxamide 22b (201 mg, 0.846 mmol) was reacted according to general procedure A with 
K2CO3, bromoacetaldehyde diethyl acetal (1 eq, 2nd portion = 0.2 eq) at µW 180 °C (2 × 15 min). Crude 
product was obtained as a yellow oil (246 mg, 92%) which was used without further purification. LCMS: 
Rt = 2.37 min, 89 A% @ 254 nm, [M + H]+ = 318.2. 1H NMR (600 MHz, CDCl3) δ 7.79 (t, J = 6.3 Hz, 
1H), 7.40 – 7.34 (m, 4H), 7.34 – 7.30 (m, 1H), 7.14 (d, J = 1.0 Hz, 1H), 7.01 (d, J = 1.0 Hz, 1H), 4.79 (t, 
J = 5.5 Hz, 1H), 4.61 (d, J = 6.3 Hz, 2H), 4.60 (d, J =5.5 Hz, 2H), 3.77 (dq, J = 9.4, 7.0 Hz, 2H), 3.52 
(dq, J = 9.4, 7.0 Hz, 2H), 1.20 (t, J = 7.0 Hz, 6H). 13C NMR (100 MHz, CDCl3) δ 159.0, 138.5, 137.9, 
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128.7, 127.7, 127.5, 127.4, 126.3, 101.9, 64.0, 50.8, 43.1, 15.2. HRMS (ESI): m/z calcd for 
C34H46N6NaO6 [2M + Na]+, 657.3371; found, 657.3392.
2-Nitro-6-phenylimidazo[1,2-a]pyrazin-8(7H)-one; 24a
Compound 27a (230 mg, 0.839 mmol) was reacted according to general procedure C to yield a crystalline 
yellow solid (181 mg, 84%). Mp = 342 °C (decomposed). LCMS: Rt = 3.05 min, 99 A% @ 254 nm, [M 
+ H]+ = 257.0. 1H NMR (600 MHz, DMSO-d6) δ 11.97 (s, 1H), 8.79 – 8.73 (s, 1H), 7.83 (s, 1H), 7.71 – 
7.64 (m, 2H), 7.57 – 7.48 (m, 3H). 13C NMR (150 MHz, DMSO-d6) δ 153.6, 147.9, 134.6, 132.1, 130.7, 
129.9, 129.0, 126.8, 116.7, 104.6. HRMS (ESI): m/z calcd for C12H8N4NaO3 [M + Na]+, 279.0489; found, 
279.0482.
2-Nitro-6-phenylimidazo[1,2-a]pyrazin-8(7H)-one; 24a
Imidazole-2-carboxamide 13a (450 mg, 2.34 mmol) was reacted according to general procedure E with
2-bromoacetophenone (1.2 eq) in anh. DMF (20 vol). HCl (2M aq., 20 vol) was then added slowly and 
reaction was then heated (µW 120 °C for 1 h, 150 °C for 15 min) and the product isolated to yield a 
brown solid (242 mg, 40%). LCMS: Rt = 3.02 min, 98 A% @ 254 nm, [M + H]+ = 257.0. 1H NMR (600 
MHz, DMSO-d6) δ 11.99 (s, 1H), 8.77 (s, 1H), 7.83 (s, 1H), 7.69 – 7.67 (m, 2H), 7.55 – 7.50 (m, 3H). 
Proton spectrum consistent with preparation using 4-nitroimidazole 21a as starting material.
2-((2-Nitro-6-phenylimidazo[1,2-a]pyrazin-8-yl)oxy)ethyl acetate; 24b and 2-(2-nitro-8-oxo-6-
phenylimidazo[1,2-a]pyrazin-7(8H)-yl)ethyl acetate; 24c
Imidazopyrazinone 24a (280 mg, 1.09 mmol) was reacted according to general procedure A with K2CO3 
and 2-bromoethylacetate (2 × 1.5 eq) with heating (2 × µW 80 °C, 30 min). The crude material contained 
imidazopyrazinone (minor) and imidazopyrazine (major) isomers in a 1:5.7 ratio by NMR. The crude 
material was purified over C18 silica gel by MPLC (Grace Reveleris, A: H2O + 0.1% TFA, B: ACN + 
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0.1% TFA, 20–100% B) to yield imidazopyrazine as a yellow solid (231 mg, 62%) and 
imidazopyrazinone as a yellow solid (19 mg, 5%). Minor isomer imidazopyrazinone 24b: LCMS: Rt 
= 2.59 min, 99 A% @ 254 nm, [M + H]+ = 343.0. 1H NMR (600 MHz, DMSO-d6) δ 8.74 (s, 1H), 7.60 – 
7.52 (m, 5H), 7.50 (s, 1H), 4.10 – 4.02 (m, 4H), 1.89 (s, 3H). 13C NMR (150 MHz, DMSO-d6) δ 170.0, 
153.3, 148.1, 134.6, 134.1, 131.3, 129.9, 129.8, 128.8, 116.1, 106.8, 60.7, 43.4, 20.6. HRMS (ESI): m/z 
calcd for C16H14N4Na1O5 [M + Na]+, 365.0856; found, 365.0858. Major isomer imidazopyrazine 24c: 
LCMS: Rt = 2.93 min, 99 A% @ 254 nm, [M + H]+ = 343.0. 1H NMR (600 MHz, DMSO-d6) δ 8.95 (s, 
1H), 8.86 (s, 1H), 8.03 – 7.98 (m, 2H), 7.57 – 7.51 (m, 2H), 7.49 – 7.43 (m, 1H), 4.89 – 4.84 (m, 2H), 
4.53 – 4.48 (m, 2H), 2.05 (s, 3H). 13C NMR (150 MHz, DMSO-d6) δ 170.3, 153.0, 148.4, 136.8, 135.0, 
129.5, 129.2, 128.9, 125.7, 115.1, 111.9, 65.0, 62.0, 20.7. HRMS (ESI): m/z calcd for C16H14N4Na1O5 
[M + Na]+, 365.0856; found, 365.0861. 
7-(2-Hydroxyethyl)-2-nitro-6-phenylimidazo[1,2-a]pyrazin-8(7H)-one; 24d
Compound 24b (19 mg, 55 µmol) was reacted according to general procedure D. After 25 min volatiles 
were removed under a stream of N2. The residue was diluted with H2O (2 mL) then extracted with EtOAc 
(3 × 2 mL) followed by DCM (3 × 2 mL). The organic layer was further diluted with EtOAc (14 mL), 
washed with brine (20 mL), dried with anh. MgSO4 and filtered. Volatiles were removed in vacuo to give 
a yellow residue which was purified over silica gel by MPLC (Grace Reveleris X2, 4–15% MeOH in 
DCM) then over C18 silica gel by MPLC (Grace Reveleris, A: H2O + 0.1% TFA, B: ACN + 0.1% TFA, 
15–40% B) to yield a yellow-brown solid (3.8 mg, 17%). LCMS: Rt = 2.52 min, 99 A% @ 254 nm, [M 
+ H]+ = 301.1. 1H NMR (600 MHz, DMSO-d6) δ 8.73 (s, 1H), 7.59 – 7.51 (m, 5H), 7.46 (s, 1H), 4.77 (s, 
1H), 3.85 (t, J = 6.3 Hz, 2H), 3.43 (br t, J = 6.7 Hz, 2H). 13C NMR (150 MHz, DMSO-d6) δ 153.2, 148.0, 
135.1, 134.4, 131.7, 129.9, 129.7, 128.6, 115.9, 106.5, 57.5, 46.6. HRMS (ESI): m/z calcd for 
C14H12N4Na1O4 [M + Na]+, 323.0751; found, 323.0759.
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2-((2-Nitro-6-phenylimidazo[1,2-a]pyrazin-8-yl)oxy)ethan-1-ol; 24e
Compound 24c (146 mg, 0.427 mmol) was reacted according to general procedure D, work-up procedure 
B. The crude material was purified by MPLC (Grace Reveleris X2, A: H2O + 0.1% TFA, B: ACN + 
0.1% TFA, 30–100% B) to yield a bright yellow solid (13 mg, 10%). LCMS: Rt = 3.36 min, 98 A% @ 
254 nm, [M + H]+ = 301.0. 1H NMR (600 MHz, DMSO-d6) δ 8.94 (s, 1H), 8.83 (s, 1H), 8.04 – 7.98 (m, 
2H), 7.57 – 7.51 (m, 2H), 7.49 – 7.43 (m, 1H), 4.69 – 4.64 (m, 2H), 3.91 – 3.86 (m, 2H). 13C NMR (150 
MHz, DMSO-d6) δ 153.4, 148.3, 137.0, 135.1, 129.6, 129.1, 128.9, 125.7, 115.0, 111.6, 68.7, 58.9. 
HRMS (ESI): m/z calcd for C14H12N4NaO4 [M + Na]+, 323.0751; found, 323.0756.
6-Methyl-2-nitroimidazo[1,2-a]pyrazin-8(7H)-one; 25a
Imidazole-2-carboxamide 16a (1.50 g, 7.79 mmol) was reacted according to general procedure E with
chloroacetone (1.3 eq) to yield a yellow solid (1.01 g, 67%). LCMS: Rt = 2.35 min, 99 A% @ 254 nm, 
[M + H]+ = 195.0. 1H NMR (600 MHz, DMSO-d6) δ 11.66 (s, 1H), 8.76 (s, 1H), 7.34 – 7.29 (m, 1H), 
2.12 (d, J = 1.2 Hz, 3H). 13C NMR (150 MHz, DMSO-d6) δ 153.4, 147.7, 134.4, 129.5, 116.2, 103.9, 
15.7. HRMS (ESI): m/z calcd for C14H12N8NaO6 [2M + Na]+, 411.0772; found, 411.0782.
2-(6-Methyl-2-nitro-8-oxoimidazo[1,2-a]pyrazin-7(8H)-yl)ethyl acetate; 25b and 2-((6-methyl-2-
nitroimidazo[1,2-a]pyrazin-8-yl)oxy)ethyl; 25c
Compound 25a (150 mg, 0.773 mmol) was reacted according to general procedure A with K2CO3 and 2-
bromoethyl acetate (2 × 2 eq) with heating (2 × µW 80 °C, 30 min). The crude material contained 
imidazopyrazinone (major) and imidazopyrazine (minor) isomers in a 2.4:1 ratio by NMR. The crude 
solid was purified over silica gel by MPLC (Grace Reveleris X2, 0–10% MeOH in DCM gradient) to 
yield imidazopyrazinone as a yellow solid (140 mg, 48%) and imidazopyrazine as a yellow solid (57 mg, 
21%). Major isomer imidazopyrazinone 25b: LCMS: Rt = 2.80 min, 99 A% @ 254 nm, [M + H]+ = 
281.1. 1H NMR (600 MHz, DMSO-d6) δ 8.76 (s, 1H), 7.45 (q, J = 1.2 Hz, 1H), 4.27 (t, J = 5.6 Hz, 2H), 
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4.21 (t, J = 5.5 Hz, 2H), 2.35 (d, J = 1.2 Hz, 3H), 1.98 (s, 3H). 13C NMR (150 MHz, DMSO-d6) δ 170.2, 
153.4, 147.9, 133.8, 131.2, 115.7, 104.8, 61.1, 42.4, 20.6, 16.8. HRMS (ESI): m/z calcd for C11H13N4O5 
[M + H]+, 281.0880; found, 281.0878. Minor isomer imidazopyrazine 25c: LCMS: Rt = 3.23 min, 99 
A% @ 254 nm, [M + H]+ = 281.1. 1H NMR (600 MHz, DMSO-d6) δ 8.96 (s, 1H), 8.06 (q, J = 1.1 Hz, 
1H), 4.70 – 4.65 (m, 2H), 4.46 – 4.41 (m, 2H), 2.33 (d, J = 1.1 Hz, 3H), 2.05 (s, 3H). 13C NMR (151 
MHz, DMSO) δ 170.4, 152.8, 148.1, 136.9, 129.0, 114.4, 112.4, 64.8, 62.0, 20.7, 20.4. HRMS (ESI): 
m/z calcd for C11H13N4O5 [M + H]+, 281.0880; found, 281.0890.
7-(2-Hydroxyethyl)-6-methyl-2-nitroimidazo[1,2-a]pyrazin-8(7H)-one; 25d
Imidazopyrazinone 25b (50 mg, 0.18 mmol) was reacted according to general procedure D, work-up 
procedure B. The crude material was purified over C18 silica gel by MPLC (Grace Reveleris, A: H2O + 
0.1% TFA, B: ACN + 0.1% TFA, 5–25% B) to yield a yellow solid (35 mg, 83%). LCMS: Rt = 2.42 
min, 99 A% @ 254 nm, [M + H]+ = 239.0. 1H NMR (600 MHz, DMSO-d6) δ 8.75 (s, 1H), 7.42 (q, J = 
1.2 Hz, 1H), 4.95 (t, J = 5.8 Hz, 1H), 4.02 (t, J = 5.7 Hz, 2H), 3.64 (q, J = 5.7 Hz, 2H), 2.36 (d, J = 1.2 
Hz, 3H). 13C NMR (150 MHz, DMSO-d6) δ 153.3, 147.9, 134.0, 132.0, 115.5, 104.3, 58.1, 45.9, 17.3. 
HRMS (ESI): m/z calcd for C18H20N8NaO8 [2M + Na]+, 499.1296; found, 499.1296.
2-((6-Methyl-2-nitroimidazo[1,2-a]pyrazin-8-yl)oxy)ethan-1-ol; 25e 
Imidazopyrazine 25c (20 mg, 71 µmol) was reacted according to general procedure D, work-up 
procedure B. The crude material was purified over C18 silica gel by MPLC (Grace Reveleris, A: H2O + 
0.1% TFA, B: ACN + 0.1% TFA, 10–30% B) to yield a yellow solid product (11 mg, 67%). LCMS: Rt 
= 2.78 min, 99 A% @ 254 nm, [M + H]+ = 239.0. 1H NMR (600 MHz, DMSO-d6) δ 8.94 (s, 1H), 8.03 
(q, J = 1.1 Hz, 1H), 5.00 (t, J = 5.5 Hz, 1H), 4.51 – 4.46 (m, 2H), 3.84 – 3.78 (m, 2H), 2.32 (d, J = 1.1 
Hz, 3H). 13C NMR (150 MHz, DMSO-d6) δ 153.3, 148.1, 137.1, 129.2, 114.3, 112.0, 68.6, 58.9, 20.5. 
HRMS (ESI): m/z calcd for C18H20N8NaO8 [2M + Na]+, 499.1296; found, 499.1315. 
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6-Methyl-2-nitro-7-(4-(trifluoromethoxy)benzyl)imidazo[1,2-a]pyrazin-8(7H)-one; 25f and 6-
methyl-2-nitro-8-((4-(trifluoromethoxy)benzyl)oxy)imidazo[1,2-a]pyrazine; 25g
Compound 25a (150 mg, 0.773 mmol), K2CO3, and 1-(bromomethyl)4-(trifluoromethoxy)benzene (1.2 
eq) were reacted according to general procedure A at rt for 3 h, work-up B. The crude material contained 
imidazopyrazinone (major) and imidazopyrazine (minor) isomers in a 7.2:1 ratio by NMR. The crude 
solid was purified over silica gel by MPLC (Grace Reveleris X2, 0–7% MeOH in DCM gradient) to yield 
imidazopyrazinone as an off-white solid (197 mg, 69%) and imidazopyrazine as a colorless solid (27 mg, 
9%). Major isomer imidazopyrazinone 25f: LCMS: Rt = 3.52 min, 99 A% @ 254 nm, [M + H]+ = 
369.0. 1H NMR (600 MHz, DMSO-d6) δ 8.81 (s, 1H), 7.50 (q, J = 1.2 Hz, 1H), 7.40 – 7.36 (m, 2H), 7.36 
– 7.32 (m, 2H), 5.31 (s, 2H), 2.21 (d, J = 1.2 Hz, 3H). 13C NMR (150 MHz, DMSO-d6) δ 153.7, 148.0, 
147.4, 136.1, 134.0, 131.0, 128.3, 121.4, 120.1 (q, J = 256.4 Hz), 115.9, 105.2, 45.3, 16.6. HRMS (ESI): 
m/z calcd for C15H12F3N4O4 [M + H]+, 369.0805; found, 369.0803. Minor isomer imidazopyrazine 25g: 
LCMS: Rt = 3.86 min, 99 A% @ 254 nm, [M + H]+ = 369.1. 1H NMR (600 MHz, DMSO-d6) δ 8.96 (s, 
1H), 8.08 (q, J = 1.1 Hz, 1H), 7.72 – 7.66 (m, 2H), 7.46 – 7.41 (m, 2H), 5.58 (s, 2H), 2.36 (d, J = 1.1 Hz, 
3H). 13C NMR (151 MHz, DMSO) δ 152.7, 148.2, 148.2, 137.0, 135.3, 130.6, 129.1, 121.1, 120.1 (q, J 
= 257.1 Hz), 114.4, 112.5, 67.2, 20.4. HRMS (ESI): m/z calcd for C15H12F3N4NaO4 [M + Na]+, 391.0625; 
found, 391.0629.
6-Methyl-7-(4-methylbenzyl)-2-nitroimidazo[1,2-a]pyrazin-8(7H)-one; 25h and 6-methyl-8-((4-
methylbenzyl)oxy)-2-nitroimidazo[1,2-a]pyrazine; 25i
Compound 25a (150 mg, 0.773 mmol) was reacted according to general procedure method A with 
Cs2CO3 and 4-methylbenzyl bromide (1.2 eq) with heating (µW 80 °C for 10 min, then 90 °C at 10 min) 
followed by rt overnight, work up B. The crude material contained imidazopyrazinone (major) and 
imidazopyrazine (minor) isomers in a ratio of 1.8:1 by LC-MS (UV 254 nm). The crude product was 
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purified over silica gel by MPLC (Biotage Isolera, 0-4% DCM/MeOH) to give imidazopyrazinone as 
light yellow powder (150 mg, 65%) and imidazopyrazine as a light orange solid (21 mg, 9%). Major 
isomer imidazopyrazinone 25h: LCMS: Rt = 2.92 min, 99 A% @ 254 nm, [M+H]+  = 299.1. 1H NMR 
(600 MHz, DMSO-d6) δ 8.79 (s, 1H), 7.48 (d, J = 1.3 Hz, 1H), 7.17 – 7.08 (m, 4H), 5.24 (s, 2H), 2.27 
(s, 3H), 2.20 (d, J = 1.3 Hz, 3H); 13C NMR (150 MHz, DMSO-d6) δ 153.6, 148.0, 136.4, 133.9, 133.5, 
131.1, 129.2, 126.1, 115.8, 105.0, 45.5, 20.6, 16.5. HRMS (ESI): m/z calc for C15H14N4O3Na [M+Na]+: 
321.0958, found 321.0957. Minor isomer imidazopyrazine 25i: LCMS: Rt = 3.26 min, 99 A% @ 254 
nm, [M+H]+  = 299.1; 1H NMR (600 MHz, DMSO-d6) δ 8.94 (d, J = 0.9 Hz, 1H), 8.06 (t, J = 1.1 Hz, 
1H), 7.43 (d, J = 7.8 Hz, 2H), 7.23 (d, J = 7.7 Hz, 2H), 5.49 (s, 2H), 2.36 (d, J = 1.1 Hz, 3H), 2.32 (s, 
3H); 13C NMR (150 MHz, DMSO-d6) δ 152.9, 148.1, 137.7, 137.0, 132.7, 129.1, 129.0, 128.7, 114.3, 
112.3, 68.1, 20.8, 20.4. HRMS (ESI): m/z calc for C15H14N4O3Na [M+Na]+: 321.0958, found 321.0958.
6-Methyl-2-nitro-7-(3-(trifluoromethoxy)benzyl)imidazo[1,2-a]pyrazin-8(7H)-one; 25j
Compound 25a (120 mg, 0.618 mmol), Cs2CO3, and 1-(bromomethyl)-3-(trifluoromethoxy)benzene (1.2 
eq) was reacted according to general procedure A with heating (µW 80 °C) for 10 min, work-up B.  The 
crude material contained imidazopyrazinone (major) and imidazopyrazine (minor) isomers in a ratio of 
4.3:1 by LC-MS (UV 254 nm). The crude product was purified over silica gel by MPLC (Biotage Isolera, 
2-4% DCM/MeOH) to give imidazopyrazinone as white powder (122 mg, 54%) and imidazopyrazine as 
white solid. Major isomer imidazopyrazinone 25j: LCMS: Rt = 3.49 min, 99 A% @ 254 nm, [M+H]+  
= 368.8. 1H NMR (600 MHz, DMSO-d6) δ 8.80 (s, 1H), 7.51 – 7.45 (m, 2H), 7.32 – 7.23 (m, 3H), 5.33 
(s, 2H), 2.20 (d, J = 1.3 Hz, 3H). 13C NMR (150 MHz, DMSO-d6) δ 153.7, 148.6, 147.9, 139.5, 134.0, 
130.9, 130.7, 125.2, 120.0 (q, J = 256.9 Hz), 119.6, 119.1, 115.9, 105.2, 45.4, 16.6. HRMS (ESI): m/z 
calc for C15H11F3N4O4Na [M+Na]+: 391.0624, found 391.0625. Minor isomer imidazopyrazine 25k: 
LCMS: Rt = 3.79 min, 65 A% @ 254 nm, [M+H]+  = 368.8; Impurity detected at Rt = 4.03 min, 35 A% 
@ 254 nm, [M+H]+  = 737.2. This compound was not subjected to biological evaluation.
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6-Methyl-2-nitro-7-(2-(trifluoromethoxy)benzyl)imidazo[1,2-a]pyrazin-8(7H)-one; 25l and 6-
methyl-2-nitro-8-((2-(trifluoromethoxy)benzyl)oxy)imidazo[1,2-a]pyrazine; 25m
Compound 25a (120 mg, 0.618 mmol), Cs2CO3, and 2-(trifluoromethoxy)benzyl bromide (1.2 eq) were 
reacted according to general procedure A with heating (µW 80 °C) for 10 min, work-up B. The crude 
material contained imidazopyrazinone (major) and imidazopyrazine (minor) isomers in a ratio of 1.3:1 
by LC-MS (UV 254 nm). The crude product was purified over silica gel by MPLC (Biotage Isolera, 0-
4% DCM/MeOH) to yield imidazopyrazinone as white powder (76 mg, 33%) and imidazopyrazine as 
cream powder (cream powder, 18 mg, 8%). Major isomer imidazopyrazinone 25l: LCMS: Rt = 3.48 
min, 99 A% @ 254 nm, [M+H]+  = 369.0; 1H NMR (600 MHz, DMSO-d6) δ 8.83 (s, 1H), 7.54 (d, J = 
1.3 Hz, 1H), 7.49 – 7.42 (m, 2H), 7.36 – 7.30 (m, 1H), 7.11 (dt, J = 7.8, 1.0 Hz, 1H), 5.30 (s, 2H), 2.18 
(d, J = 1.2 Hz, 3H. 13C NMR (150 MHz, DMSO-d6) δ 153.6, 148.0, 145.6, 133.9, 130.8, 129.2, 128.7, 
127.9, 127.1, 120.8, 120.2 (q, J = 257.4 Hz), 116.0, 105.4, 41.3, 16.2. HRMS (ESI): m/z calc for 
C15H11F3N4O4Na [M+Na]+: 391.0625, found 391.0613. Minor isomer imidazopyrazine 25m: LCMS: 
Rt = 3.78 min, 99 A% @ 254 nm, [M+H]+  = 369.0; 1H NMR (600 MHz, DMSO-d6) δ 8.96 (s, 1H), 8.09 
(d, J = 1.3 Hz, 1H), 7.75 (dd, J = 7.6, 1.7 Hz, 1H), 7.57 (td, J = 7.9, 1.8 Hz, 1H), 7.51 – 7.44 (m, 2H), 
5.63 (s, 2H), 2.36 (d, J = 1.1 Hz, 3H); 13C NMR (150 MHz, DMSO-d6) δ 152.5, 148.2, 146.8, 136.9, 
131.4, 130.6, 128.9, 128.3, 127.7, 120.6, 120.1 (q, J= 256.4 Hz), 114.4, 111.6, 62.5, 20.3. HRMS (ESI): 
m/z calc for C15H11F3N4O4Na [M+Na]+: 391.0625, found 391.0621.
5,6-Dimethyl-2-nitroimidazo[1,2-a]pyrazin-8(7H)-one; 26a
Imidazole-2-carboxamide 16a (750 mg, 3.89 mmol) was reacted according to general procedure E with
3-bromo-2-butanone (1.5 eq) to yield a yellow solid (477 mg, 67%). LCMS: Rt = 2.57 min, 99 A% @ 
254 nm, [M + H]+ = 209.1. 1H NMR (600 MHz, DMSO-d6) δ 11.55 (s, 1H), 8.82 (s, 1H), 2.32 (q, J = 1.0 
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Hz, 3H), 2.16 (q, J = 1.0 Hz, 3H). 13C NMR (150 MHz, DMSO-d6) δ 152.8, 147.9, 134.6, 124.6, 115.2, 
111.0, 14.7, 12.5. HRMS (ESI): m/z calcd for C16H16N8NaO6 [2M + Na]+, 439.1085; found, 439.1090.
6-Methyl-2-nitro-7-(4-(trifluoromethoxy)benzyl)imidazo[1,2-a]pyrazin-8(7H)-one; 26b and 5,6-
dimethyl-2-nitro-8-((4-(trifluoromethoxy)benzyl)oxy)imidazo[1,2-a]pyrazine; 26c
Compound 26a (150 mg, 0.721 mmol) was reacted according to general procedure A with K2CO3 and 1-
(bromomethyl)4-(trifluoromethoxy)benzene (1.2 eq) at rt overnight. The ratio of 26b:26c in the crude 
material was 3:1 (NMR). The crude solid was purified over silica gel by MPLC (Grace Reveleris X2, 0–
7% MeOH in DCM gradient) to yield 26b as a yellow solid (178 mg, 69%) and 25c as a yellow solid (57 
mg, 21%). Major isomer imidazopyrazinone 26b: LCMS: Rt = 3.61 min, 99 A% @ 254 nm, [M + H]+ 
= 383.1. 1H NMR (600 MHz, DMSO-d6) δ 8.93 (s, 1H), 7.38 – 7.31 (m, 4H), 5.37 (s, 2H), 2.43 (q, J = 
1.0 Hz, 3H), 2.23 (q, J = 1.0 Hz, 3H). 13C NMR (150 MHz, DMSO-d6) δ 153.2, 148.1, 147.4, 136.3, 
133.9, 128.2, 126.3, 121.4, 120.1 (q, J = 256.1 Hz), 115.3, 112.5, 45.7, 14.9, 13.9. HRMS (ESI): m/z 
calcd for C16H14F3N4O4 [M + H]+, 383.0962; found, 383.0958. Minor isomer imidazopyrazine 26c: 
LCMS: Rt = 3.94 min, 99 A% @ 254 nm, [M + H]+ = 383.0. 1H NMR (600 MHz, DMSO-d6) δ 9.03 (s, 
1H), 7.70 – 7.65 (m, 2H), 7.45 – 7.40 (m, 2H), 5.56 (s, 2H), 2.54 (q, J = 0.9 Hz, 3H), 2.40 (q, J = 0.9 Hz, 
3H).13C NMR (150 MHz, DMSO-d6) δ 150.8, 148.5, 148.1, 135.6, 132.8, 130.5, 129.4, 121.1, 120.6, 
120.1 (q, J = 255.5 Hz), 113.2, 66.8, 19.6, 13.7. HRMS (ESI): m/z calcd for C16H14F3N4O4 [M + H]+, 
383.0962; found, 383.0961.
5,6-Dimethyl-7-(4-methylbenzyl)-2-nitroimidazo[1,2-a]pyrazin-8(7H)-one; 26d and 5,6-dimethyl-
8-((4-methylbenzyl)oxy)-2-nitroimidazo[1,2-a]pyrazine; 26e
Compound 24a (65 mg, 0.312 mmol) was reacted according to general procedure A with Cs2CO3 and 4-
methylbenzyl bromide (1.2 eq) with heating (µW 80 °C, 20 min then µW 90 °C, 10 min) followed by 
stirring overnight at rt, work up B. The ratio of 26d:26e in the crude material was 1.5:1 by LC-MS (UV 
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254 nm). The crude was purified over silica gel by MPLC (Biotage Isolera, 0-4% DCM/MeOH) to yield 
26d as a yellow powder (39 mg, 40%) and 26e as a light yellow powder (18 mg, 19%). Major isomer 
imidazopyrazinone 26d: LCMS: Rt = 3.45 min, 99 A% @ 254 nm, [M+H]+  = 313.1. 1H NMR (600 
MHz, DMSO-d6) δ 8.90 (s, 1H), 7.14 (d, J = 7.9 Hz, 2H), 7.08 (d, J = 8.1 Hz, 2H), 5.30 (s, 2H), 2.42 (d, 
J = 1.0 Hz, 3H), 2.27 (s, 3H), 2.22 (d, J = 1.0 Hz, 3H). 13C NMR (150 MHz, DMSO-d6) δ 153.2, 148.1, 
136.4, 133.9, 133.7, 129.3, 126.5, 126.1, 115.2, 112.3, 46.0, 20.6, 14.8, 13.8. HRMS (ESI): m/z calc for 
C16H16N4O3Na [M+Na]+: 335.1115, found 335.1116. Minor isomer imidazopyrazine 26e: Rt = 3.81 
min, 99 A% @ 254 nm, [M+H]+  = 313.1. 1H NMR (600 MHz, DMSO-d6) δ 9.01 (s, 1H), 7.44 – 7.40 
(m, 2H), 7.25 – 7.20 (m, 2H), 5.48 (s, 2H), 2.55 – 2.52 (m, 3H), 2.40 (d, J = 1.0 Hz, 3H), 2.32 (s, 3H). 
13C NMR (150 MHz, DMSO-d6) δ 151.0, 148.4, 137.5, 132.9, 132.8, 129.4, 128.9, 128.7, 120.3, 113.1, 
67.7, 20.8, 19.6, 13.6. HRMS (ESI): m/z calc for C16H16N4O3Na [M+Na]+: 335.1115, found 335.1115.
5,6-Dimethyl-2-nitro-7-(3-(trifluoromethoxy)benzyl)imidazo[1,2-a]pyrazin-8(7H)-one; 26f and 
5,6-dimethyl-2-nitro-8-((3-(trifluoromethoxy)benzyl)oxy)imidazo[1,2-a]pyrazine; 26g
Compound 26a (120 mg, 0.576 mmol) was reacted according to general procedure A with Cs2CO3 and 
1-(bromomethyl)-3-(trifluoromethoxy)benzene (1.2 eq) with heating (µW 100 °C) for 10 min. The ratio 
of 26f:26g in the crude material was 1.2:1 by LC-MS (UV 254 nm). The crude material was purified 
over silica gel by MPLC (Biotage Isolera, 0-4% dichloromethane/methanol) to yield 26f as a light brown 
solid (131 mg, 60%) and 26g as a yellow gel (66 mg, 30%). Major isomer imidazopyrazinone 26f: 
LCMS: Rt = 3.56 min, 99 A% @ 254 nm, [M+H]+  = 383.1. 1H NMR (600 MHz, DMSO-d6) δ 8.93 (s, 
1H), 7.51 – 7.43 (m, 1H), 7.29 (s, 1H), 7.28 – 7.21 (m, 2H), 5.39 (s, 2H), 2.43 (d, J = 1.1 Hz, 3H), 2.24 
– 2.20 (m, 3H). 13C NMR (150 MHz, DMSO-d6) δ 153.3, 148.6, 148.1, 139.7, 133.9, 130.7, 126.2, 125.1, 
120.0 (q, J = 256.2 Hz), 119.6, 119.0, 115.2, 112.4, 45.8, 14.9, 13.9. HRMS (ESI): m/z calc for 
C32H26F6N8O8Na [2M+Na]+: 787.1678, found 787.1670. Minor isomer imidazopyrazine 26g: LCMS: 
Rt = 3.88 min, 99 A% @ 254 nm, [M+H]+  = 383.1. 1H NMR (600 MHz, DMSO-d6) δ 9.03 (s, 1H), 7.61 
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– 7.51 (m, 3H), 7.40 – 7.35 (m, 1H), 5.58 (s, 2H), 2.54 (s, 3H), 2.39 (s, 3H). 13C NMR (150 MHz, DMSO-
d6) δ 150.7, 148.5, 148.3, 138.8, 132.7, 130.5, 129.4, 127.5, 120.9, 120.9, 120.7, 120.0 (q, J = 256.2 Hz), 
113.2, 66.8, 19.6, 13.7. HRMS (ESI): m/z calc for C16H13F3N4O4Na [M+Na]+: 405.0797, found 405.0781.
5,6-Dimethyl-2-nitro-7-(2-(trifluoromethoxy)benzyl)imidazo[1,2-a]pyrazin-8(7H)-one; 26h and 
5,6-dimethyl-2-nitro-8-((2-(trifluoromethoxy)benzyl)oxy)imidazo[1,2-a]pyrazine; 26i
Compound 26a (120 mg, 0.576 mmol) was reacted according to general procedure A with Cs2CO3 and 
2-(trifluoromethoxy)benzyl bromide (1.2 eq) with heating (µW 100 °C) for 10 min. The ratio of 26h:26i 
in the crude material was 1:2.1 by LC-MS (UV 254 nm). The crude material was purified over silica gel 
by MPLC (Biotage Isolera, 0-4% DCM/MeOH) to yield 26h as a light yellow powder (46 mg, 21%) and 
26i as a light yellow powder (97 mg, 44%). Minor isomer imidazopyrazinone 26h: LCMS: Rt = 3.15 
min, 99 A% @ 254 nm, [M+H]+  = 383.1. 1H NMR (600 MHz, DMSO-d6) δ 8.95 (s, 1H), 7.48 – 7.41 
(m, 2H), 7.35 – 7.29 (m, 1H), 7.06 (dt, J = 8.0, 1.0 Hz, 1H), 5.36 (s, 2H), 2.45 (d, J = 1.0 Hz, 3H), 2.19 
(d, J = 1.0 Hz, 3H). 13C NMR (150 MHz, DMSO-d6) δ 153.1, 148.1, 145.6, 133.8, 129.2, 128.9, 127.9, 
127.1, 126.1, 120.9, 120.3 (q, J = 256.8 Hz), 115.3, 112.6, 41.7, 14.5, 13.9. HRMS (ESI): m/z calc for 
C16H13N4O4F3Na [M+Na]+: 405.0781, found 405.0796. Major isomer imidazopyrazine 26i: LCMS: Rt 
= 3.44 min, 99 A% @ 254 nm, [M+H]+  = 383.1. 1H NMR (600 MHz, DMSO-d6) δ 9.03 (s, 1H), 7.74 
(dd, J = 7.6, 1.8 Hz, 1H), 7.55 (td, J = 7.8, 1.8 Hz, 1H), 7.50 – 7.43 (m, 2H), 5.61 (s, 2H), 2.54 (d, J = 
0.9 Hz, 3H), 2.39 (d, J = 1.0 Hz, 3H). 13C NMR (150 MHz, DMSO-d6) δ 150.6, 148.5, 146.8, 132.7, 
131.3, 130.5, 129.3, 128.5, 127.7, 120.8, 120.6, 120.2 (q, J = 256.8 Hz), 113.2, 62.2, 19.6, 13.6. HRMS 
(ESI): m/z calc for C16H13N4O4F3Na [M+Na]+: 405.0781, found 405.0793.
4-Nitro-1-(2-oxo-2-phenylethyl)-1H-imidazole-2-carboxamide; 27a
Compound 16a (1.20 g, 5.53 mmol), K2CO3 and 2-bromoacetophenone (1.1 eq) were reacted according 
to general procedure A at rt for 1 h. The crude was purified over silica gel by MPLC (Grace Reveleris 
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X2 15–100% EtOAc in pet. spirits gradient) to yield an orange oily-solid (907 mg, 60%). LCMS: Rt = 
3.15 min, 98 A% @ 254 nm, [M + H]+ = 274.9. 1H NMR (600 MHz, DMSO-d6) δ 8.52 (s, 1H), 8.24 (s, 
1H), 8.08 – 8.02 (m, 2H), 7.78 – 7.72 (m, 2H), 7.66 – 7.59 (m, 2H), 6.13 (s, 2H). Minor impurities in 1H 
NMR. 13C NMR (150 MHz, DMSO-d6) δ 191.9, 159.3, 144.5, 137.7, 134.3, 134.0, 129.1, 128.0, 126.4, 
55.7. HRMS (ESI): m/z calcd for C12H10N4NaO4 [M + Na]+, 297.0594; found, 297.0592.
Minimum Inhibition Concentration (MIC) Assay
All compounds were tested for activity against C. difficile bacteria (630, ATCC BAA-1382) and 
representative ESKAPE pathogens S. aureus (MRSA, ATCC 43300), E. coli (FDA control strain, ATCC 
25922), K. pneumoniae (MDR, ATCC 700603), A. baumannii (type strain, ATCC 19606) and P. 
aeruginosa (quality control strain, ATCC 27853) and fungi C. albicans (CLSI reference, ATCC 90028) 
and C. neoformans (H99 type strain, ATCC 208821) using a standard broth microdilution assay 
essentially as previously described.49 MICs for each strain were determined as the lowest concentration 
without visible growth. Variance between replicates was typically within one 2-fold dilution. Median 
MICs are reported with a range given when the median MIC was between two tested concentrations.
M. tuberculosis H37Rv Minimum Inhibition Assays
The potency of the inhibitors was measured by a resazurin reduction microplate assay as previously 
described50,51 with some alterations. M. tuberculosis (H37Rv) was grown in Middlebrook 7H9 broth 
medium supplemented with ADC (Difco Laboratories), 0.5% glycerol, and 0.02% Tyloxapol. Freshly 
seeded cultures were grown at 37 °C for approximately 14 days to mid-exponential phase (OD600 0.4−0.8) 
for use in the inhibition assays. Assay plates (96-well microtiter) were prepared with compound serially 
diluted in 100 µL of 7H9S media (7H9 with 10% ADC, 0.5% glycerol, 0.05% Tween-80 and 1% 
tryptone). Mid-exponential phase culture of M. tuberculosis (OD600 0.4−0.8) was diluted to OD600 0.001 
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in 7H9S media and 100 μL (representing ∼2 x 104 CFU/mL) was added to each well. For normoxic 
conditions, the plates were incubated for 5 days at 37 °C in a humidified incubator prior to the addition 
of 30 μL of a 0.02% resazurin solution and 12.5 μL of 20% Tween-80 to each well. After 24 h incubation 
(37 °C), sample fluorescence was measured on a Fluorostar Omega fluorescent plate reader (BMG) with 
an excitation wavelength of 530 nm and emission read at 590 nm. Percent fluorescence relative to the 
positive control wells (H37Rv without compound) minus the negative control wells (without H37Rv) 
was plotted for the determination of the MIC (≤90% reduction in growth). The assays were performed in 
replicate on independent occasions (n = 3–6). For hypoxic assays the same method was used except assay 
plates were incubated for 5 days at 0.1% oxygen and after addition of the resazurin solution the 
fluorescence was measured after a prolonged incubation time of 48 h.
Antiparasitic Assay: G. lamblia and E. histolytica
Compounds were screened for antiparasitic activity in a 96-well plate using an ATP-bioluminescence 
based assay for cell growth and survival as previously described.49 Briefly, trophozoites of G. lamblia 
(WB line52) and E. histolytica (HM1:IMSS) were axenically maintained in TYI-S-33 medium 
supplemented with penicillin (100 U/mL) and streptomycin (100 μg/mL).53 All experiments were 
performed using trophozoites harvested during the logarithmic phase of growth. Two-fold serial dilutions 
were prepared from compound stocks (10 mM in DMSO) yielding a concentration range of 78 µM–10 
mM. From this dilution plate, 0.5 μL from each well was transferred into 96-well microtitre plates 
followed by addition of 99.5 μL of trophozoites (5000 parasites) to yield a final 8-point concentration 
range spanning 0.39–50 μM. Assay plates were incubated for 24–48 h at 37 °C in the GasPak™ EZ 
Anaerobe Gas Generating Pouch Systems (VWR, West Chester, PA) to maintain anaerobic condition 
throughout the incubation period. Viable cell numbers were determined in triplicate using the CellTiter-
Glo Luminescent Cell Viability Assay.54
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Antiparasitic Assay: T. b. brucei
Compounds were screened for antitrypanosomal activity against T. b. brucei (strain 427, BS427) 
using an established 384-well resazurin viability assay, as previously described.55-57 Briefly, 55 µL of 
HMI-9 media supplemented with 10% FCS containing 1200 cells/mL of logarithmic phase T. b. brucei 
bloodstream parasites were added to a 384-well microtiter plate (BD biosciences, USA) and incubated 
for 24 hrs at 37 °C/5% CO2. Serial compound concentrations were prepared in 100% DMSO and diluted 
1:21 in DMEM media. Five microliters of these dilutions were subsequently added to assay plates to give 
final compound concentrations ranging from a top final assay concentration of 40 or 20 µM, to 4x10-3 
µM or 2x10-3 µM, respectively. Plates were incubated for 48 hrs at 37 °C/5% CO2. Ten microlitres of 
0.49 mM resazurin (Sigma-Aldrich, USA) in HMI-9 media +10% FCS was added to assay plates and 
incubated for a further 2 hrs at 37 °C/5% CO2 followed by 22 hrs at room temperature. Final assay 
concentrations of puromycin (5 μM) and 0.4% DMSO were used as in-plate controls for all experiments. 
Assay plates were read at 535 nm excitation/590 nm emission on an Envision® multiplate reader 
(PerkinElmer, USA). Non-linear sigmoidal dose response curves with no constraints were plotted and 
IC50 values calculated in GraphPad Prism 6. The IC50 value was determined for compounds that exhibited 
a plateau of inhibition (above 90% inhibition at the top two concentrations) and were calculated from 
two independent experiments.
Antiparasitic Assay: Leishmania donovani Intracellular Amastigote 
Compounds were screened for antileishmanial activity in an established DD8 intracellular (THP-1) 
amastigote assay as previously described.57 Briefly, seven day old L. donovani MHOM/IN/80/DD8 
(ATCC50212) culture containing metacyclic promastigotes were added to the 384-well assay plates 
containing the transformed THP-1 cells (ATCC TIB202) at 72 hrs after the initial cell seeding with a 
multiplicity of infection (MOI) of 1:5 (ratio host cells : parasites). Assay plates were incubated 24 hrs at 
37˚C / 5% CO2. Non-internalised parasites were removed by washing 6 times in PBS before the addition 
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of 45 μL RMPI (10% FBS and 25 ng/mL phorbol 12-myristate 13-acetate). Five microliters of 
compounds were added to wells to give final assay concentrations ranging from 80 to 4x10-3 μM. Final 
assay concentrations of 2 μM of amphotericin B and 0.4% DMSO were used as in-plate controls for all 
experiments. Plates were incubated for 96 hr at 37˚C / 5% CO2, fixed with 4% paraformaldehyde and 
stained with SYBR® green and CellMask™ Deep Red plasma membrane dye. Images were acquired on 
an Opera high-content imaging system (PerkinElmer). Healthy host (THP-1) cells were identified based 
on fluorescent staining with CellMask Deep Red to characterize the cytoplasm in which the parasite 
resides and SYBR green to identify both host and parasite nuclei. An infected cell was defined as a host 
cell containing >3 parasites within the cytoplasm boundary. Non-linear sigmoidal dose response curves 
with no constraints were plotted and IC50 values calculated in GraphPad Prism 6. The IC50 value was 
determined for compounds that exhibited a plateau of inhibition (above 90% inhibition at the top two 
concentrations) and were calculated from two independent experiments.
Mammalian Cytotoxicity Assay
Human HEK293 and HepG2 cells were seeded at 3000 and 5000 cells per well in 384-well plates, 
respectively. Cells were cultured in Dulbecco's modified Eagle's medium with 10% FBS for 24 h at 
37 °C, 5% CO2. A dilution series of compounds was added, with the highest concentration of 100 μM. 
The final concentration of DMSO in culture media was 0.5%, which showed no effect on cell growth. 
After 24 h incubation with the compounds, 5 μM resazurin was added into each well and incubated at 
37 °C for 2 h. As a negative control, 1% Triton X-100 was added into the culture media to lyse all of the 
cells. The fluorescence intensity was read using Polarstar Omega with excitation/emission 560/590 nm. 
Data were analyzed with GraphPad Prism 6 software (La Jolla, California USA) to calculate CC50 values.
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Microsome Stability
Metabolic stability was determined using pooled human (HMMC-PL, Lot# PL050B-B, Thermo Fisher 
Scientific USA) and mouse (CD-1) (MCMCPL, Lot#MS033D, Thermo Fisher) liver microsomes. Test 
compound (3 μM, final DMSO concentration 0.2%) and liver microsomes (1 mg/mL) were mixed in 
100 mM potassium phosphate buffer, pH 7.4 preincubated at 37 °C (500 μL volume). The reaction was 
initiated by addition of NADPH solution (cofactor) in 0.1 M potassium phosphate buffer at a final 
NADPH concentration of 1 mM. The reaction was incubated in a shaking incubator at 37 °C, 150 rpm. 
Aliquots (90 μL) from the reaction mixture were withdrawn (t = 0, 10, 30, 60 and 120 min) and quenched 
by adding ice-cold precipitating solution (270 μL) comprising 0.5 μM carbutamide internal standard in 
acetonitrile: methanol: formic acid (1: 1: 0.001 v/v). Reaction samples were incubated at 4 °C for 30 min, 
centrifuged at 14,000 × g for 8 min and the clear supernatant was analyzed by LC/MS/MS. The 
percentage of compound remaining at different times was calculated by comparing the peak area ratio of 
the parent compound (compound peak area/internal standard peak area) at the start of incubation 
(t = 0 min sample). All samples were tested in triplicate except for the control samples (without 
NADPH), matrix blank and verapamil standard (time points = 0, 10 and 30 min). LC/MS/MS parameters 
are detailed in the Supporting Information Table S4.
Plasma Stability
Plasma stability studies were performed using human (HMPLNAHP, Lot#BRH1324758, 
BioReclamationIVT) and mouse (CD-1) plasma (MSEPLNAHP, Lot#MSE261215, 
BioReclamationIVT) at five different time points. A solution of plasma and phosphate buffer saline 
(PBS), pH 7.4 (50:50; v/v) were pre-heated at 37 °C for 30 min (240 μL volume). The reaction was 
initiated by addition of the test compounds (3 μM, final DMSO concentration 1%) and the reaction was 
incubated in a shaking incubator at 37 °C, 150 rpm. Aliquots (40 μL) from the reaction mixture were 
Page 69 of 90
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
withdrawn and processed as described for microsome stability assay. All samples were tested in triplicate 
and eucatropine was used as a positive control.
Plasma Protein Binding
Plasma Protein Binding (PPB) was performed using an Ultrafiltration method.58,59 Fresh frozen human 
plasma was pooled from O Positive (Product Number 2799882) and O Negative (Product number 
5398256) blood from the R & D division of the Australian Red Cross Blood Services (Brisbane). Test 
compounds (5 μM) were incubated in 100% human plasma at 37 °C for 30 min (1 mL volume). For 
unfiltered samples, an aliquot (50 μL) was removed, diluted with PBS (50 μL) and quenched with ice-
cold precipitating solution comprising 0.5 μM carbutamide MS internal standard in acetonitrile: 
methanol: formic acid (1: 1: 0.001). Samples were incubated at 4 °C for 30 min, then centrifuged at 
14,000 × g for 8 min before the clear supernatant was transferred to a vial for LC/MS/MS analysis. For 
filtered samples, the plasma sample (250 μL) was filtered using Amicon Ultra-0.5 Centrifugal Filter 
Devices 30K NMWL at 14,000 × g for 7 min and then an aliquot (50 μL) was processed as described for 
unfiltered samples. The fraction of unbound compound was calculated by determining the concentration 
of the filtered sample and the concentration of unfiltered sample. All samples were tested in triplicate 
with sulfamethoxazole as a control.
Caco-2 Permeability Assay
This study was conducted by WuXi AppTec Co. Ltd. (Shanghai). Caco-2 cells from ATCC were seeded 
onto polystyrene membranes in 96-well insert plate at 1 × 105 cells/cm2 until the formation of confluent 
cell monolayer at 21st‒28th day. Transport buffer used was HBSS with 10 mM HEPES, pH 7.4. 
Compounds (2 µM) were tested bidirectionally in duplicate. The plate was incubated for 2 h at 37 °C and 
5% CO2 at saturated humidity without shaking. All samples were then mixed with acetonitrile containing 
internal standard, centrifuged at 4000 rpm for 20 min and the clear supernatant was diluted 1:1 with water 
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prior to LC/MS/MS analysis. Test compounds and controls (fenoterol, propranolol and digoxin) in 
starting solution, donor solution, and receiver solution were quantified using peak area ratio of 
analyte/internal standard. To confirm the Caco-2 cell monolayer integrity after the transport assay, lucifer 
yellow rejection assay was performed. The apparent permeability coefficient Papp (cm/s) was calculated 
using the equation: Papp = (dCr/dt) × Vr / (A × C0) where dCr/dt is the cumulative concentration of 
compound in the receiver chamber as a function of time (µM/s); Vr is the solution volume in the receiver 
chamber (0.075 mL on the apical side, 0.25 mL on the basolateral side); A is the surface area for the 
transport, i.e. 0.0804 cm2 for the area of the monolayer; C0 is the initial concentration in the donor 
chamber (µM). The efflux ratio was calculated using the equation: Efflux Ratio = Papp (BA) / Papp (AB). 
Percent recovery was calculated using the equation: % Recovery = 100 x [(Vr × Cr) + (Vd × Cd)] / (Vd × 
C0) where Vd is the volume in the donor chambers (0.075 mL on the apical side, 0.25 mL on the 
basolateral side); Cd and Cr are the final concentrations of transport compound in donor and receiver 
chambers, respectively.
Solubility Determination
Stock compound solution (20 mM in DMSO) was aliquoted into water and phosphate buffer saline 
(PBS), pH 7.4 and 0.1 M HCl (pH 1) respectively to a final concentration of 200 μM, 1% DMSO. After 
24 hours of incubation in a shaking incubator at room temperature, 130 rpm, solutions were filtered using 
centrifuge filter tubes (Corning® Costar® Spin-X® centrifuge tube filters, CLS8169) at 8,000 rpm for 1 
min. The filtrates were further diluted with acetonitrile (1:1, v/v) prior to analysis using LC/UV as 
detailed in the general experimental. The solubility was determined based on the peak area at UV 
absorbance 254 nm, with reference to the standard calibration curve prepared from 20 mM DMSO stock. 
Compounds and standards (caffeine and pretomanid) were prepared in duplicate and each sample was 
analyzed in duplicate by LC/UV.
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Supporting information
1H and 13C NMR Spectra
2D NMR and crystal structure data (Figure S1, Tables S1-S3) for 17a
LC/MS/MS detection and analysis parameters for plasma protein binding and metabolic stability Table 
S4
Supplementary biological data Tables S5-S8
Solubility data Table S9
Molecular formula strings (CSV)
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